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ABSTRACT 
 
Background: Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) are reported to be 
associated with an increased risk of malignancy. Newfoundland and Labrador (NL) has one 
of the highest cancer rates in Canada. There is a paucity of literature on the prevalence of 
malignancy in NL patients diagnosed with RA and PsA. We hypothesize that the risk of 
malignancy in these groups of patients is higher compared to the NL general population. 
Objective: Evaluate the incidence of malignancy and precancerous lesions in a cohort of 
PsA and RA patients and compare rates with the general population. Evaluate the impact 
of therapy and chronic inflammation on these two diseases. 
Methods: Data were extracted from the charts of 700 arthritis patients (68% female) seen 
at a local rheumatology clinic between 2011 and 2014. Statistical analyses were performed 
using SPSS v. 21.0 (IBM Inc.). Overall cancer incidence rates were calculated per 100,000 
person-years. Observed rates were compared with the rates in the NL general population. 
Multivariate regression analysis was used to assess association between incident cancers 
and explanatory variables. 
Result: The results suggest no significant difference in cancer rates between the cohort and 
the NL general population (P<0.3217). We identified 37(5.3%) different types of cancers. 
Etanercept and combination therapy (Biologics (bDMARDs) and Methotrexate (MTX)) 
showed significant risk reduction: (OR=0.1, 95% CI, 0.01-0.89, P=0.039) and (OR=0.3, 
95% CI, 0.02-0.44, P=0.003) respectively.  
Conclusion: There is no difference in the cancer rate between our study and the NL general 
population. We also concluded that the analyzed data was reassuring due to OR values less 
than 1 (OR 0.3, P=0.003) for combined therapy of MTX and Biologics. More 
epidemiologic studies are required to determine the cancer prevalence in NL population. 
Key Words: Malignancies, Psoriatic Arthritis, Rheumatoid Arthritis, Biologic Disease 
Modifiers (bDMARDs). 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Introduction to the Thesis   
Psoriatic Arthritis (PsA) and Rheumatoid Arthritis (RA) both belong to a larger 
family of diseases known as Immune-Mediated Inflammatory Disorders (IMIDs). IMIDs 
are defined as a group of chronic and highly disabling diseases involving excessive immune 
responses caused or accompanied by cytokine dysregulation and acute or chronic 
inflammation (Williams & Meyers, 2002).  Apart from PsA and RA, IMIDs include a wide 
variety of other illnesses, such as Psoriasis (PsO), Crohn’s disease (CD), Ankylosing 
Spondylitis (AS) and Systemic Lupus Erythematosus (SLE). These disorders are known to 
be relatively common and are believed to affect an estimated 5% to 7% of the population 
in Western countries (Beyaert et al., 2013). Although PsA and RA are accounting only for 
2% of the of the general population they have a high burden of cost and disability (PHAC, 
https://www.canada.ca/en/public-health/services ).  
The most common clinical presentation of PsA and RA is arthritis. The Public 
health agency of Canada (PHAC, http://www.phac-aspc.gc.ca) and the Center for Disease 
Control and Prevention (CDC, https://www.cdc.gov) in the United States (US) have 
reported arthritis as one of the most prevalent chronic health conditions. It was also reported 
to be the leading cause of disability and use of health care resources. Between 2010-2014, 
approximately 4.8 million (16.5%) Canadians aged 15 and older (PHAC, http://www.phac-
aspc.gc.ca) and 54.4 million US adults (22,7%) (CDC, https://www.cdc.gov) were 
diagnosed with arthritis. In Canada, these rates have shown a stable trend since 2007 with 
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around (12%) for males and (19%) for females. Females were more likely than males to 
have arthritis from 45 years of age and older. 
1.2 Arthritis in Canada and Newfoundland and Labrador 
In 2007-2008, the crude prevalence of arthritis varied considerably across Canada, 
(PHAC, http://www.phac-aspc.gc.ca). The highest prevalence of individuals who reported 
having arthritis was found in Nova Scotia (NS) (23%), followed by Newfoundland and 
Labrador (NL) (21%), New Brunswick (NB) and Prince Edward Island (PEI) (20% and 
19%, respectively). The province of Quebec (QC) (12%) and the Territories (Yukon (YT), 
Northwest Territories (NT) and Nunavut (NU) (11%) had the lowest percentage of 
individuals who reported arthritis (PHAC, http://www.phac-aspc.gc.ca).   
A more recent 2014 report showed an increase in NL arthritis prevalence rate by 4.4% 
reaching the highest rate throughout Canada (25.4%) (http://www.statcan.gc.ca/tables-
tableaux/sum-som/l01/cst01/health52b-eng.htm). 
Generally, all Atlantic Canadian provinces had comparatively higher prevalence of 
inflammatory arthritis as compared to other parts of the country (NB and NS-25.0% each, 
PEI- 21.2%). The province of Manitoba (MB) (19%), Ontario (ON) (18.3%) and Yukon 
(17.3%) were in second palace. The remaining provinces British Columbia (BC), Alberta 
(AB), and the North West Territories shared near to similar rates of 16% each. The lowest 
rate of disease remained in NU (11.7%) and QC (11.0%). 
In addition, PHAC has reported arthritis to be the third most common chronic 
condition in adult Canadian women and men (19.2% vs 12.6%) after back pain (22.2% 
vs19.8%) and high blood pressure (17.6 vs 16.4%) respectively. Newfoundland and 
Labrador has also shown to have the highest rates of chronic disease in Canada 
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(http://www.health.gov.nl.ca). In 2005, the Government of Newfoundland and Labrador 
released a report on the prevalence of chronic diseases in the province (Government of 
Newfoundland and Labrador, Department of Health and Community Services, Provincial 
Healthy Aging Policy Framework, page 37). The report showed higher prevalence rates of 
many chronic conditions in NL seniors as compared to the rest of Canada: arthritis (51.9% 
vs 45.9%), high blood pressure (50.0% vs 44.0%), diabetes (19.7 % vs 14.6%), asthma 
(10.8 %vs 7.4%) and obesity (15.4% vs15.1%). As the NL population ages, the prevalence 
of chronic diseases is expected to grow. According to the statistical prognostic model, with 
the aging of the “baby boomers” generation in NL, the number of people with arthritis is 
expected to increase from 92,000 in 2011 to 127,000 in 2036, with the largest increase 
occurring among adults aged 65 years and older. This in turn, will increase the utilization 
of healthcare services as well as resources. Furthermore, statistics published by the Public 
Health Agency of Canada (PHAC, http://www.phac-aspc.gc.ca) have shown that over 4.8 
million Canadians (16.5 %) reported having arthritis, and with the continued growth of the 
Canadian aging population, this number is expected to increase to approximately 7 million 
(20%) by 2031. Although arthritis is known to be most prevalent among seniors, it is not 
necessarily limited to the elderly population and many people are affected in the prime of 
their younger years. In 2008, 17.2% of males and 24.8% of females ages 45 to 64 
(representing more than 1.9 million people) reported a diagnosis of arthritis 
(http://www.statcan.gc.ca).   
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CHAPTER 2 
 LITERATURE REVIEW 
 
2.1 Details of Search Strategy 
In order to gain a better insight and a broader perspective of the issue at hand, a 
literature search and review was conducted. The aim of the review was to examine different 
perceptions and knowledge gaps amongst existing literature regarding cancer risk in 
patients with Inflammatory Arthritis. The following electronic databases were used:  
PUBMED (MEDLINE), Embase and Cochrane Library using the following key words and 
MESH terms: (("Neoplasm OR cancer OR malignancy [MESH])) AND “Arthritis 
Rheumatoid” [MESH] “Arthritis Psoriatic” [MESH])) AND “Tumor Necrosis Factor-
alpha/antagonists and inhibitors”. The search term “Tumor Necrosis Factor-
alpha/antagonists and inhibitors” was used mainly because TNFi’s are most commonly 
prescribed biologics in PsA and RA patients and have been widely used for more than 15 
years allowing for cancer incidence in latent cancers to occur. Additional filters were set 
at: Humans; Adults and English. For environmental scan, Google and Google Scholar were 
used to help consult with public websites such as Canadian Cancer Statistics, Public Health 
Agency of Canada (PHAC), World Health Organization (WHO), Newfoundland and 
Labrador Center for Health Information (NLCHI), Arthritis Community Research and 
Evaluation Unit (ACREU), as well as Newfoundland and Labrador Government Health 
websites. Relevant study references were also scanned for possible related citations. The 
initial combined search yield 1044 citations (Fig 2.1) that were imported into RefWorks. 
Articles were first selected based on the relevance of their title. Pertinent articles (n=85) 
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included in the final review (after removal of duplicates and those that did not meet our 
inclusion criteria) are discussed below.    
 
Fig 2.1 Prisma Flow Chart of Selected Articles 
 
 
  
N= 1,039 potentially relevant 
publications identified and 
screened for retrieval 
 
 
N= 5 additional sources were 
identified through scanning of 
references 
 
 
N=1,044 articles imported into RefWorks 
 N= 356 duplicates were removed 
 
N= 688 records screened 
through their titles and 
abstracts 
 
               N= 532 Excluded 
• Not   PsA or RA  
• Not TNF/ 
bDMARDS  
 
N= 156  
Full text articles were 
assessed for eligibility 
 
N= 71 Full text articles excluded  
           failed quality criteria 
 
 
N= 85 studies included in the 
final review 
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2.2 Reviewed Literature 
The literature review showed disagreements amongst studies regarding the risk of 
malignancy in patients with Inflammatory Arthritis (PsA and RA). Some studies have 
reported increased malignancy risk, others low risk, whereas a number of studies indicated 
no risk between their study population and comparison groups. Over the past decades, the 
question of association of incidence of malignancy with this group of systemic 
inflammatory diseases has been studied and debated. Even though the existing literature is 
inconclusive, the available evidence is sufficient to speculate a heightened risk of 
malignancies in this group of patients.  
 2.2 a) Studies for Increased Cancer Risk  
Evidence from a number of previous studies has shown increased rates of 
malignancy among people with inflammatory arthritis (Askling et al., 2005; Beyaert et al., 
2013; Y. Chen, Chang, Wang, & Wu, 2011; Smitten, Simon, Hochberg, & Suissa, 2008). 
Chen et al. (2011) investigated the relative risk of cancer in 23,644 Taiwanese RA patients 
for over a period of eleven years. To do so, they used the Taiwanese National Health 
Insurance database. The authors in this study observed 935 cancers in patients with RA. 
Their study results further showed that patients with RA had a significant increased risk of 
cancer (SIR= 2.74, 95% CI, 2.68–2.81). Among hematologic cancers, the risk of non-
Hodgkin's lymphoma was greatest (SIR= 3.54, 95% CI, 3.45–3.63). Although this study 
had numerous strengths such as large sample size and long duration of follow-up, it was 
also limited by an inadequate adjustment for important prognostic factors that likely 
impacted the validity of their results. Several important confounding factors such as 
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smoking, alcohol use and body mass index were not adjusted for. Smoking for instance, is 
a known strong risk factor for lung and other cancers (Pesch et al., 2012). In another study, 
Smitten et al., 2008 conducted a systematic literature review and meta-analysis of 21 
articles from 1990-2007. The main objective was to characterize the associated risk of 
overall malignancy and four site-specific malignancies (lymphoma, lung, colorectal, and 
breast cancer) in patients with RA.  The authors of this study observed that RA patients 
have approximately a two-fold increase in lymphoma risk (SIR= 2.08, 95% CI,1.80 - 2.39) 
when compared with the general population. The risk of lung cancer was also significantly 
increased with a SIR of (1.63, 95% CI, 1.43 - 1.87). The authors of this study concluded 
that patients with RA are at higher risk of lymphoma and lung cancer, though at a decreased 
risk for colorectal and breast cancer compared with the general population. In 2005, 
Askling et al. in a population- based study, described the cancer pattern of RA patients. 
They conducted the study on three RA cohorts: one prevalent (n = 53 067), one incident 
(n = 3703), and one with patients treated with TNF- antagonists (n = 4160). These cohorts 
were linked with Swedish nationwide cancer registers. In the prevalent cohort, the study 
results showed a minimally increased overall risk of solid cancer (SIR =1.05, 95% CI, 1.01 
- 1.08). Lung cancers were significantly more common than expected in both prevalent and 
incident cohorts (SIR= 1.48, 95% CI, 1.33 - 1.65) and (SIR= 2.4, 95% CI, 1.5 - 3.6), 
respectively. Whereas, the occurrence of non-melanoma skin cancer was significantly 
increased in TNF -inhibitor treated patients cohorts (SIR =3.6, 95% CI, 1.8 -6.5).  
  
 8 
2.2 b) Cancer Association with Chronic Inflammation and Treatment  
So far, the risk of developing precancerous lesions and their progression to cancer 
has been mainly associated with chronic systemic inflammation, disease progression, 
duration, and with their treatment modalities, particularly biological disease modifying 
antirheumatic drugs (bDMARDs).  
2.2 b.1) Chronic Inflammation and Cancer 
The association between chronic systemic inflammation and cancer is complex and 
controversial. Inflammation is known to have both pro- and anti-tumorigenic effects. 
Recent literature has expanded the concept that inflammation is an important component 
of cancer formation (Hiraku et.al., 2014). In addition, cancer-related inflammation is now 
considered the eighth hallmark of cancer after genome instability and mutation (Hanahan 
& Weinberg, 2011). The hallmarks of cancer are underlying principles shared by all cancers 
such as: 1) self-sufficiency in growth signals 2) insensitivity to antigrowth signals 3) 
evading apoptosis 4) limitless replicative potential 5) sustained angiogenesis 6) tissue 
invasion and metastasis and 7) genome instability and mutation (Hanahan & Weinberg, 
2011). 
 Pro-Tumorigenic Effect: The pro-tumorigenic effect of chronic inflammation can initiate 
tumors by directly causing DNA changes or making cells more susceptible to mutagens 
(Kiraly, Gong, Olipitz, Muthupalani, & Engelward, 2015). In addition, inflammation can 
act as a tumor promoter. Inflammatory mediators including cytokines (TNF, interleukin IL-
1 and IL-6, growth factors and others) produced by tumor-associated lymphocytes and 
macrophages, can enhance tumor cell growth and metastasis by promoting their survival, 
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proliferation, and invasion of other tissues. Tumor-associated macrophages (TAMs) are 
one of the most important players in the inflammation and cancer arena. They are an 
important source of cytokines that release inflammatory mediators that stimulate tumor- 
angiogenesis (Mantovani, Allavena, Sica, & Balkwill, 2008). TAMS produce cytokines, 
including transforming growth factor (TGF) β and IL-10, which can directly suppress 
immune responses (Hiraku, Kawanishi, & Ohshima, 2014). At the molecular level, the 
transcription factor NF-kB appears to be a key connecting element between inflammation 
and cancer (Grivennikov, Greten, & Karin, 2010; Ben-Neriah & Karin, 2011). 
Baecklund et al. (2006) performed a case-control study of 378 Swedish RA patients 
in whom malignant lymphoma occurred between 1964 and 1995 and 378 controls. Their 
aim was to investigate which patients were at highest cancer risk, and whether 
antirheumatic treatment was hazardous or protective. The authors noted that the risk of 
lymphoma is substantially increased in patients with RA with very severe disease. They 
concluded that high inflammatory activity, rather than its treatment was the major cancer 
risk determinant. Another group of authors detailed the importance of pro-inflammatory 
cytokines such as IL-1β, TNF-α and IL -6 in inflammation and cancer development (Hiraku 
et al. 2014). They pointed out that these cytokines can promote cell growth, supress 
apoptotic cell death and stimulate production of growth factors. 
 Anti-Tumorigenic Process: The anti-tumorigenic process involves activation of 
inflammatory cells (neutrophils, macrophages, monocytes, T and B lymphocytes- and 
others) by the immune system to destroy a developing tumor (Dunn, Old, & Schreiber, 
2004). It is a process that was originally envisioned by Ehrlich in 1909 and in 1957-1959, 
was formalized by Burnet and Thomas and renamed as “cancer immune-surveillance.” In 
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this process, M1 macrophages, (activated by IFNγ and microbial products) express high 
levels of pro-inflammatory cytokines (TNF-α, IL-1, IL-6, IL-12 or IL-23), major 
histocompatibility complex (MHC) molecules, inducible nitric oxide synthase and are 
capable of killing pathogens and priming anti-tumor immune responses (Grivennikov, 
Greten, & Karin, 2010). MHC- complexes on the surfaces of transformed or malignant cells 
are recognized and targeted for elimination by the immune system. Recent experiments in 
mice have demonstrated scenarios in which developing tumors are indeed recognized and 
destroyed by the intact immune system (Dunn, Bruce, Ikeda, Old, & Schreiber, 
2002);(Smyth, Dunn, & Schreiber, 2006). In contrast, “Cancer Research UK” 
(http://www.cancerresearchuk.org/) demonstrated that even though immune cells can 
attack fledgling tumors by infiltrating them in an inflammatory response, instead of killing 
it, the tumor uses the nutrients and oxygen that are part of the inflammatory response to 
fuel its own growth. Therefore, even though tumor associated inflammatory cells appear to 
be actively recruited as part of an anti-tumor response, the tumor is not killed but instead 
this inflammatory response may be apprehended by the tumor to promote tumorigenesis 
(Beyaert et al., 2013). 
2.2 b.2) Inflammatory Arthritis (PsA/RA) Treatment and Cancer 
The primary objectives in managing PsA and RA patients were to timely control 
inflammation, prevent tissue damage, and as much as possible, secure the long-term 
remission of the disease. In the past, this has been mainly achieved by using corticosteroids, 
anti-malarias and disease modifying agents (DMARDs) such as sulfasalazine and 
methotrexate. With the advent of biologic disease modifying agents (bDMARDs), 
especially tumor necrosis factor (TNF)-alfa antagonists (inhibitors) that suppress 
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inflammatory pathways, the treatments of these diseases have undergone a revolutionary 
change (Beyaert et al., 2013). TNF-alpha inhibitors represent important treatment advances 
for several inflammatory conditions, including Psoriatic Arthritis (PsA) and Rheumatoid 
Arthritis (RA). Generally, these agents are considered to be safe and well tolerated, but 
because they possess immunosuppressive properties, which can affect 
“immunosurveillance” (a process believed to help suppress the development of cancer), 
there have been concerns that immunotherapies might increase cancer risk in patients 
receiving this treatment. Lately, there is expressed concern about the risk of infection and 
malignancy associated with these agents. Tumor necrosis factor (TNF)- alpha is a bioactive 
cytokine (a chemical produced by the immune system) that causes inflammation in the 
body and is an important component of the inflammatory and pain pathways 
(http://www.rheumatology.org). Inhibition of TNF-alpha can decrease the inflammatory 
response. This cytokine, however, can play a double role: a) defensive, by stimulating 
natural killer (NK) and cytotoxic T- lymphocytes (CTL) (that can mediate killing of tumor 
cells), and b) offensive, as a mediator of cancer promoting inflammation (Balkwill, 2009). 
Consequently, TNF-alpha inhibitors may hypothetically either promote or block cancer 
growth (Raval et al., 2010). 
Over the past years, the role of Inflammatory Arthritis therapies in the development 
of malignancies has been a subject of a vast debate. A number of studies in the reviewed 
literature highlighted the impact of therapy on cancer risk in patients with PsA and RA. 
While some studies have found an increased risk of malignancy with the use of these drugs 
(Askling et al., 2005; Bongartz et al., 2006; Beyaert et al., 2013; Kavanaugh, et al., 2009; 
Mariette et al., 2010), others have not found any significant increase in the rate of 
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malignancy between experimental and control groups (Dommasch et al., 2011; Haynes et 
al., 2013., Hellgren et al., 2014; Gross et al., 2014; Mercer et al., 2012; Rohekar et al., 2008; 
Wu et al 2014).  Askling et al. (2005), in a Swedish population-based study, observed that 
patients with Rheumatoid Arthritis who were treated with TNF- alpha antagonist were at a 
70% increased risk for non-melanoma skin cancers (NMSC). The occurrence of NMSC 
was significantly increased in patients treated with TNF-alpha inhibitors (SIR =1.66, 95% 
CI, 1.50 -1.84). Beyaert et al.’s (2013) review discussed the effect on cancer risk of different 
drug classes used in IMIDs treatment, including TNF-alpha inhibitors. They reported an 
overall increased cancer risk for patients with rheumatoid arthritis and psoriasis, with risk 
profiles differing for different tumor types. Mariette et al. (2010), used national registries 
to prospectively collect all cases of lymphoma and opportunistic infections occurring in 
RA patients receiving anti-TNF blockers. They also examined the results from nationwide 
prospective cohorts to investigate the safety and efficacy of rituximab (RTX), abatacept 
(ABA) and tocilizumab (TZC) in RA and other autoimmune diseases. Their study results 
showed that the risk of opportunistic infections, TB and lymphoma were higher with anti-
TNF. Patients receiving adalimumab or infliximab had a higher risk of lymphoma than 
those treated with etanercept: SIR (95% CI) 4.1 (2.3, 7.1) and 3.6 (2.3, 5.6) vs 0.9 (0.4, 
1.8). The preliminary reports from nationwide prospective cohorts showed that patients in 
real life have frequent comorbidities (e.g. history of cancer in 13% of patients receiving 
RTX and 5% of patients receiving ABA). However, no results for Tocilizumab (TZC) were 
presented as the study recruitment was still ongoing.  
 Contrarily to the above, several other studies did not observe any increased risk 
and have demonstrated similar or decreased cancer rates in patients with PsA and /or RA 
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and their comparison group (Dommasch et al., 2011; Haynes et al., 2013., Hellgren et al., 
2014; Gross et al., 2014; Mercer et al., 2012; Wu et al 2014). Dommasch et al.’s (2011) 
systematic review of 20 randomized controlled trials of TNF antagonists for psoriasis (PsO) 
and psoriatic arthritis (PsA) patients did not observe any significant evidence of increased 
risk in cancer with short-term use of TNF inhibitors (TNFi). This study, however, was 
limited by inclusion of clinical trials that had a short duration of follow-up (average of 17.8 
weeks) to look at a rear event as an outcome.  Hellgren et al. (2014) used the Swedish 
National Patient Register to assess the risk of Lymphoma in AS (n = 8,707) and patients 
with PsA (n = 19,283) treated with TNFi therapy. The numbers and incidence of lymphoma 
were not significantly different in TNFi-exposed versus TNFi-naive AS and PsA patients, 
although the numbers of lymphomas in this study were small. The authors concluded that 
TNFi does not affect the risk of lymphoma in AS or in PsA patients. Similarly, Haynes and 
colleagues (2013) used data from national US registries to compare the incidence of cancer 
amongst patients with IMIDs treated by TNFi versus alternative therapy: (PsA (n=2,498), 
RA (n=29,555), PsO (n=2,498) and inflammatory bowel disease IBD (n=6,357)). The 
incidence of solid cancers in this study was not elevated during TNFi therapy compared 
with alternative therapy. In another study, WU et al. (2014) conducted a 14-year nationwide 
cohort (4,426 new users of TNF- antagonists and 17,704 users of bDMARDs) using the 
Taiwan National Health Insurance Research Database. They compared the relative risk of 
cancer development between RA patients taking TNFi and those taking DMARDs. The 
risk of cancer was significantly reduced in patients in biologics cohort (HR= 0.63, 95% CI, 
0.49 to 0.80, P < .001).   
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Several large-scale clinical trials have also been performed for TNF-alpha 
inhibitors, in contrast with most non-biologic disease-modifying anti-rheumatic drugs 
(DMARDs). However, these trials have mostly reported malignancy as an adverse event, 
were limited by a short time of study duration (to enable them to look at malignancy as an 
outcome) and generally lacked an adequate post- licensure control group that would allow 
them to observe for stronger causal inference (Bongartz et al 2006; Kavanaugh, et al., 2009; 
Rubbert-Roth et al., 2016). For instance, Bongartz et al. (2006) conducted a systematic 
review and meta-analysis of randomized placebo-controlled trials to assess the extent to 
which anti-TNF therapy may increase the risk of serious infections and malignancies in 
patients with RA. They included nine randomized controlled trial (3,493) of patients who 
received anti-TNF treatment and (1,512) patients who received placebo for 12 or more 
weeks. The study results showed that there was evidence of a dose-dependent increased 
risk of malignancies in patients with Rheumatoid Arthritis treated with TNF-alpha inhibitor 
therapy. The pooled odds ratio for malignancy was (OR=3.3, 95% CI, 1.2-9.1). 
Malignancies were significantly more common in patients treated with higher doses 
compared with patients who received lower doses of anti-TNF antibodies. In another study, 
Rubbert-Roth et al. (2016) in a randomised controlled trial analysed malignancy rates in 
RA patients treated with tocilizumab ± MTX (n= 2644) and those with placebo+MTX 
(n=1454). The authors reported that malignancy rates in their study were no greater than 
those observed in placebo+MTX treated patients (1.35/100 PY (95% CI 0.65 to 2.48) and 
0.94/100 PY (95% CI 0.38 to 1.94). The authors concluded that malignancy rates remained 
stable with long-term tocilizumab treatment.  Weinblatt et al. (2013) conducted analysis of 
safety data from 8 clinical trials of RA patients (n= 4149) treated with IV abatacept, with a 
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cumulative exposure of 12,132 patient-years. The study objective was to assess the overall 
safety, including rare events, of intravenous (IV) abatacept treatment in RA patients. The 
IR of malignancies were similar for IV abatacept- and placebo-treated patients during the 
short-term period (IR =0.59, 95% CI 0.19-1.37 vs (IR= 0.73, 95% CI 0.42- 1.17). During 
the cumulative period, the IR of malignancies remained low and relatively consistent over 
time (IR=0.73, 95% CI, 0.58- 0.89). The authors concluded that long-term safety of 
Abatacept was consistent with the short-term, with no unexpected events and low incidence 
rates of serious infections and malignancies. 
Another important point worth mentioning is that, patients with Inflammatory 
Arthritis often receive other medications concomitantly with biologic agents and some 
studies have reported an associated increased risk of cancer with such practice. As an 
example, methotrexate (MTX), a traditional DMARD commonly used with TNF-alpha 
inhibitors in the treatment of RA, is shown to be associated with an elevated risk of 
Lymphoma in some studies. For instance, in a case study, Girish, Byrd, Roy, & Mehta 
(2003) reported a patient with RA in whom a rapidly enlarging B-cell lymphoma developed 
after weekly treatment with methotrexate for five years. After therapy with this drug was 
discontinued, no clinically detectable recurrence of the lymphoproliferative disorder for 
two years was observed. This study, however, was limited by its design which was a case 
-report that lacked a comparison group to support the validity of their findings.  
 
2.2 b.3) Existing Biologic Drugs Approved by Health Canada During the Study Period 
At the time of our study period there were nineteen existing biologic drugs approved 
by Health Canada (http://www.hc-sc.gc.ca/). Table 2.1 shows the most commonly used 
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biologic drugs at the study facility during the study period. Table 2.1 a) shows biologics 
that were approved by Health Canada but were beyond the scope of this study 
 
 
 
Table 2.1 Existing Biologic Drugs Approved by Health Canada During  
the Study Period 
 
  
Table 2.1 a) Approved Biologics by Health Canada Beyond the Scope of this Study 
 
 
Tumor Necrosis Factor 
Inhibitors 
(Anti-TNF) 
T-cell 
Costimulatory 
Inhibitor; 
B Lymphocyte-
Depleting 
Agent 
Interleukin 6 (IL-
6) Antagonist 
IL-1 Antagonist 
 Etanercept (ETN), Enbrel 
 Infliximab (IFX), Remicade 
 Adalimumab (ADA), Humira 
 Golimumab (GOL), Simponi 
 Cetrolizumab pegol (CTZ), 
Cimzia 
Abatacept 
(ABAT), 
Orencia 
Rituximab 
(RTX), 
Rituxan 
Tocilizumab 
(TCZ),  
Actemra 
Anakinra,  
(Kineret) 
  Biosimilars Interleukin 17 (IL-17) 
Inhibition   
Interleukin (IL-12/23) 
Blockade 
Interleukin 6 (IL-6) 
Antagonist 
IL-1 Antagonist 
 
Adalimumab-adbm, 
(Cyltezo) 
Infliximab-abda, 
(Renflexis) 
Trastuzumab-dkst, 
(Ogivr) 
 
 
 
 Secukinumab, 
(Cosentyx) 
           Ixekizumab, 
(Taltz) 
 
Ustekinumab, 
(Stelara) 
Guselkumab, 
(Tremfya) 
 
        
Sarilumab, 
(Kevzara) 
 
 
 
     Canakinumab, 
(Ilaris) 
             Rilonacept, 
(Arcalyst) 
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The most frequently prescribed traditional DMARDs are Methotrexate (MTX), 
Leflunomide (LEF), Sulfasalazine (SSZ), and Hydroxyl -Chloroquine (HCQ). 
In our study, we investigated the association of treatment and malignancy in patients 
with history of exposure to six most-often used biologics at our study site: Etanercept 
(ETN), Infliximab (IFX), Adalimumab (ADA), Golimumab (GOL), Abatacept (ABAT) 
and Rituximab (RTX), as well as traditional drugs (DMARDs), mainly Methotrexate 
(MTX), Sulfasalazine (SSZ), and Hydroxychloroquine. Additionally, we examined the 
association between Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and 
Corticosteroids (Prednisolone). 
 
2.2b.3) Food and Drug Administration (FDA) Concern Regarding TNFi 
       Initial concerns regarding a possible association between TNF-alpha inhibitor use and 
cancer arose from post -marketing reports to the US Food and Drug Administration (FDA). 
Twenty-six cases of Lymphoma (mostly non-Hodgkin Lymphoma) were reported among 
Rheumatoid Arthritis (RA) patients treated with Etanercept or Infliximab (Brown et al; 
2002). Two patients had regression of their Lymphoma when TNF- inhibitor therapy was 
discontinued; however, no comparative population was included in this report. 
Additionally, data presented to an advisory meeting of the US Food and Drug 
Administration (FDA) in 2003 included 70 cases of Lymphoma among approximately 
140,000 patients treated with Etanercept.  
Currently, several registries of rheumatic disease patients receiving bDMARDs have been 
established to provide a real life look at large cohorts. Examples of those are the Danish 
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(Hetland, 2005), British (Hyrich et al., 2006), Norwegian (Kvien et al., 2005), and Swedish 
(van Vollenhoven et al., 2005) registries. 
2.3 Rheumatoid Arthritis and Psoriatic Arthritis   
According to International Classification of Diseases (ICD-10, M05.70) and the 
National Institute of Health (NIH), Rheumatoid Arthritis (RA) is defined as: an 
inflammatory, autoimmune disease that causes pain, swelling, stiffness and loss of function 
in the joints. It occurs when the immune system, which normally defends the body from 
invading organisms, turns its attack against the membrane lining joints, which means the 
arthritis results from an immune system attacking the body's own tissues. The etiology of 
RA is unknown. Family history, genetic inherited factors, environment, hormones, 
medicine, and lifestyle changes have all been named as possible risk contributors, Public 
Health Agency of Canada (PHAC, https://www.canada.ca  ). Despite this uncertainty, it is 
generally believed that Rheumatoid Arthritis develops as a result of interaction of many 
factors. Researchers are still trying to understand these factors and how they work together.  
The course of Rheumatoid Arthritis can range from mild to severe. In most cases, it is 
chronic, meaning it lasts a long time, often a lifetime. For many people, periods of relatively 
mild disease activity are punctuated by flares, or instances of heightened disease activity. 
In others, symptoms are constant. RA often starts between ages 25 and 55 and 
symmetrically affects small and medium joints of the upper and lower extremities. It can 
also affect any other body part, including skin, eyes, heart, and lungs as well as renal, 
nervous and gastrointestinal systems. Estimates given by the World Health Organization 
(WHO http://www.who.int/en/) indicate that the world prevalence of RA varies between 
0.3% and 1% and is more common in women. 
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 Psoriatic Arthritis (PsA) (ICD-10- L 40.50) is a type of arthritis that causes joint 
pain, swelling, and stiffness in people with psoriasis. Psoriasis (PsO) is a chronic skin 
condition that causes patches of thick, inflamed red skin that are often covered with silvery 
scales. Most people who develop Psoriatic Arthritis first have skin symptoms of Psoriasis, 
followed by arthritis symptoms. However, in about 13-17 % of cases, symptoms of arthritis 
are noticed before Psoriasis appears. In another 15% of cases, Psoriatic Arthritis is 
diagnosed at the same time as Psoriasis (Gladman, DD et al; 2017) (http://www.up to 
date.com/). Nearly 30% of patients with PsO have arthritis and the prevalence is estimated 
between 0.5-1%. (Mease et al., 2013). According to Dr. Wayne Gulliver, professor of 
Medicine and Dermatology at Memorial University (MUN), close to 5 % of the NL 
population are believed to be affected by Psoriasis. Just as with RA, the cause of PsA is 
unknown.  Although both diseases seem to share some similar triggers, Psoriatic Arthritis 
differs by its asymmetrical pattern of affecting the axial (spinal) and distal (peripheral) 
interphalangeal joints. It may be characterized by the presence of Human Leukocyte 
Antigen HLA-B27 (proteins that help the body's immune system tell the difference between 
its own cells and foreign, harmful substance (https://ghr.nlm.nih.gov/primer/genefamily) 
and a negative Rheumatoid Factor (RF). The presence or absence of the RF is what defines 
these diseases to be “seropositive” or “seronegative” arthritis respectively. Unlike RA, 
which affects more women than men, Psoriatic Arthritis (PsA) affects both men and women 
equally. Regardless of the many differences in their clinical presentation, PsA and RA do 
share two very important commonalities: systemic chronic inflammation and the method 
of treatment, both of which have recently raised several questions and debates about the 
possibility of been linked to cancer formation.   
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      2.4 Etiology of Cancer  
Cancer is a tumor composed of atypical neoplastic, often pleomorphic cells that 
invades other tissues (ICD-O-3.1). There are many different types of cancers; all are 
characterized by cells that start growing abnormally and spread to other parts of the body 
(https://www.cancer.gov). Very few cancers exist that have a single, known cause. Most 
cancers seem to be the result of a complex mix of many risk factors. These risk factors may 
play different roles in starting cancer and its progression. Some risk factors include heredity 
(genetics), lifestyle choices and exposure to cancer-causing substances (carcinogens) in the 
environment. The more often and the longer the exposure to a risk factor, the greater the 
probability that cancer will develop. 
2.4 Epidemiology of Cancer 
2.4 a) Global Cancer Trend 
Cancer continues to impose an enormous burden worldwide on both economically 
developed and less developed countries alike (Torre et al. 2015). This is mainly because of 
aging populations, an increase in the prevalence of risk factors such as smoking, 
overweight, physical inactivity, changing reproductive patterns, as well as economic 
development. Estimates given by an International Agency for Research on Cancer 
(GLOBOCAN, http://gco.iarc.fr)  showed that in 2012, there were 14.1 million new cancer 
cases, 8.2 million cancer deaths and 32.6 million people were living with cancer worldwide. 
The overall age standardized cancer incidence rate is almost 25% higher in men than in 
women, with rates of 205 and 165 per 100,000, respectively. Lung cancer was reported to 
be the leading cause of cancer death among males and has surpassed breast cancer as the 
leading cause of cancer death among females in more developed countries (GLOBOCAN, 
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http://gco.iarc.fr). According to this report, Canada compares favourably to other high-
income countries on several measures, including survival and mortality rates. Canadian 
cancer incidence rate was reported as 295.72 per 100,000. Although these rates were higher 
than United Kingdom rates (UK) 272.90 per 100,000, they were lower compared to those 
of the United States (US) with 317.97 per 100,000 respectively. In the US, over the past 
decade, the overall cancer incidence rate (2004-2013) was reported to have been stable in 
women and declined by approximately 2% annually in men;  the cancer death rate (2005-
2014) declined by about 1.5% annually in both men and women (Siegel, Miller, & Jemal, 
2018). In Canada, between 1988 and 2017, the number of new cancer cases rose steadily, 
(Canadian Cancer Statistics https://www.cancer.ca). However, age standardized incidence 
rates (ASIR) as of January 2009, have decreased for males by 0.7% and increased for 
females by 0.5%. This increase is in part driven by the rise in the incidence of melanoma, 
thyroid, uterine, as well as liver cancers. 
 
2.4 b) Cancer Trend in Canada 
As the Canadian population grows and ages, the number of new cancer cases 
continues to rise steadily. Based on Canadian Cancer Statistics (https://www.cancer.ca), an 
estimated 196,900 new cases of cancer and 78,000 deaths from cancer were to occur in 
Canada in 2015. Males have a 45% lifetime probability (or a 1 in 2.2 chance) of developing 
cancer. Females had a 42% lifetime probability (or a1 in 2.4 chance) of developing cancer.  
More than half of all new cases were lung, prostate, breast, and colorectal cancers. Lung 
cancer continued to be the leading cause of cancer death, causing more cancer deaths 
among Canadians than the other three major cancer types combined.  It has been predicted 
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that two in five Canadians will develop cancer in their lifetimes and one in four will die of 
the disease. A more recent Canadian Cancer Statistics (http://www.cancer.ca) report, 
projected 206,200 new cancer cases to be diagnosed in Canada in 2017, with an equal 
number among males and females. Half of these included lung, breast, colorectal and 
prostate cancers.  
2.4 c) Cancer Trend in Newfoundland and Labrador 
The 2017 Canadian Cancer Statistics report (http://www.cancer.ca) further 
indicated that ASIR distribution of all new cancers is highest in Newfoundland and 
Labrador (586.8 per 100,000) when compared to other provinces. This was followed by 
Quebec (544.9 per 100, 000), with the lowest rates reported in Alberta (480.7 per 100,000) 
and British Columbia (461.4 per100,000). Newfoundland and Labrador also showed the 
highest rates for lung cancer in males (98.0 per 100,000), with Alberta showing the lowest 
lung cancer rates for both sexes (62.2 vs 54.6 per 100,000). Colorectal cancer rates for 
males and females were equally higher in NL (112.2 vs 76.5 per 100,00) and highest for 
females in Prince Edward Island. In addition, breast and cervical cancers in NL females 
[(152.0 per 100,000) vs (10.7 per 100,000)] and prostate in NL males (132.9 per 100,000) 
were also the highest compared to other provinces. These variations in cancer rates between 
provinces are presumed to be more likely because of differences in the prevalence of risk 
factors such as obesity, smoking, unhealthy diet and possibly testing patterns (e.g., PSA or 
mammogram cancer testing) than differences in population genetic profiles. For instance, 
in 2011, the prevalence of overweight varied from 31.3% in British Columbia to 41.8% in 
Newfoundland and Labrador. The rate for obese class I varied from 10.7% in BC to 20.5% 
in Newfoundland and Labrador (Twells, Gregory, Reddigan, & Midodzi, 2014). In 2013, 
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there was significant variation in smoking prevalence by province. Smoking rates ranged 
from a low of 11.4% in British Columbia to a high of nearly 20% in New Brunswick, 
Newfoundland & Labrador, and Nova Scotia (Reid, Hammond, Rynard, & Burkhalter, 
2014). This was a mistake. Corrections made please see below: 
Prostate cancer incidence rates have lately seen a decrease both in Canada and the 
United States, but at a faster pace than in Canada.  From 2011 to 2012, the rate in the United 
States decreased by 19.1% (http://www.cancer.ca ) compared with 12.3% in Canada 
(https://www.statcan.gc.c ). In the United States, the decline in the 2012 rate coincides with 
a significant drop in self-reported PSA screening rates. This is possibly related to revised 
guidelines released by the United States Preventive Services Task Force (USPSTF) 
(https://seer.cancer.gov/report). In 2012, the USPSTF issued a grade 'D' recommendation 
against the use of routine prostate-specific antigen (PSA) based screening for any men. In 
Canada, although the PSA screening test is widely used, it is not currently recommended 
as a population-based screening test. For instance, in Ontario the government doesn’t pay 
for the test (http://www.health.gov.on.ca).The peak  in prostate cancer incidence rates that  
occurred in Canada  in 1993 and 2000, were likely due to a detection bias as  both peaks 
coincided with two waves of intensified screening activity using the PSA test. It is therefore 
reasonable to believe that the current decline in prostate cancer rates is been seen because 
it is not been detected by screening and therefore been under diagnosed. 
Colorectal cancer mortality rates are highest in Newfoundland and Labrador for males and 
in Newfoundland and Labrador and Prince Edward Island for females. This high mortality 
rates can probably be because of poor patients compliance with screening. Based on 2007 
data from the Canadian Community Health Survey Cycle 2.1, the proportion of people who 
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reported Colorectal Cancer (CRC) screening among the four provinces assessed (Ontario, 
British Columbia, Saskatchewan, and NL) was lowest in NL at 12.6%. Only 4% of women 
in NL reported taking a fecal occult blood test (FOBT) in the 2 years before the survey was 
conducted (Sewitch, Fournier, Ciampi, & Dyachenko, 2008). 
With regards to breast cancers, the increases and fluctuations are being partly attributed to 
increase in mammography screening. Long-term changes in hormonal factors such as early 
age at menarche, breastfeeding, late age at menopause, and oral contraceptive use are also 
believed to have played a role. The sharp decrease in incidence that occurred around 2002 
may reflect the reduced use of hormone replacement therapy (HRT) among post-
menopausal women at that time. De, Neutel, Olivotto, & Morrison, (2010) observed a link 
between the declines in the use of hormone replacement therapy and breast cancer 
incidence among Canadian women aged 50-69 years, in the absence of any change in 
mammography rates.  
 In Canada, cancer also remains the leading cause of death, responsible for 30% of 
all deaths, followed by cardiovascular diseases (heart disease and cerebrovascular 
diseases), accidents and chronic lower respiratory diseases (http://www.cancer.ca). In 
2017, The Canadian Cancer Society projected the highest number of deaths 233.3 per 
100,000 (1,550 deaths) for Newfoundland and Labrador compared to other provinces. The 
province also has the highest colorectal cancer mortality rates for males followed by Prince 
Edward Island for females. 
     2.5 Psoriatic Arthritis Rheumatoid Arthritis, and Cancer  
Both PsA and RA are considered immune-mediated inflammatory diseases in which 
autoimmunity leads to the activation of certain immune cells (T- helper lymphocytes, 
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macrophages, synoviocytes -and others) and induces the production of pro-inflammatory 
cytokines such as TNFα, IL-1, and IL-6. These cytokines play an important role in both 
inflammation and cancer formation (Hiraku et al., 2014). They trigger the production of 
degradative enzymes that destroy the joints and further stimulate the T cell response. They 
also activate various transcription factors, such as nuclear factor NF- kB, signal transducer 
and activator of transcription (STAT) 3. These factors can promote cell growth, supressing 
apoptotic cell death and can activate multiple oncogenic pathways (Hiraku Y et al., 2014; 
Nakachi, Hayashi, Imai, & Kusunoki, 2004). It was observed more than a decade ago that 
significant amounts of IL-1 and TNFα are found in the joint spaces of RA patients, but not 
in those of normal controls (Hopkins & Meager, 1988). Furthermore, an early transgenic 
animal study showed that mice constitutively expressing TNF-alpha developed a chronic 
arthritis (Keffer et al., 1991) and that this arthritis could be stopped by treatment with anti-
TNF-α agents.  
Very few studies could be found that examined the risk of malignancy in patients 
with Psoriatic Arthritis when compared with Rheumatoid Arthritis. (Gross et al; 2014; 
Hagberg et al., 2016; Hellgren et al., 2014; Rohekar et al., 2008). Although PsA shares 
some clinical features with both RA and Psoriasis (PsO), the risk of malignancy has been 
better studied in the latter two. Several large cohort studies have demonstrated an increased 
risk of malignancy, particularly Lymphoma and hematologic cancers, in patients with RA 
compared with a control group (Y. Chen et al., 2011; Fantò et al., 2016; Geborek et al., 
2005 and Mellemkjaer et al.,1996). For Instance, Fanto et al. (2015) evaluated the risk of 
malignancy in 399 patients affected by RA, PsA and ankylosing spondylitis (AS) who were 
treated with TNF-alpha inhibitors and disease modifying drugs (DMARDs) or DMARDs 
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alone. Their study findings showed no overall increased cancer risk in comparison to the 
general population. However, the risk of hematologic malignancies was significantly 
higher in RA patients (SIR= 4.9, 95 CI ,1.35-12.26), particularly in females. In a study done 
by Gross et al. in 2014, comparing the incidence rates of malignancy among patients with 
Psoriatic Arthritis (PsA) and patients with Rheumatoid Arthritis (RA), an interesting point 
was made about a doubt as to whether malignancy risk in PsA patients can be elicited from 
previous studies done for patients with RA and patients with skin psoriasis. His argument 
was, since chronic inflammation is a risk factor for certain malignancies in patients with 
inflammatory arthritis (Baecklund et al., 2006) and disease activity in RA patients is 
observed to be higher in comparison with PsA patients (Reddy et al., 2010), it would only 
make sense for one to assume that RA patients stand a greater risk of cancer compared to 
PsA patients. Contrarily, one might argue that the double impact of inflammation from both 
skin disease and joint disease may equally put PsA patients at an increased risk of 
malignancy compared to patients with RA, who have only joint disease. In this study, the 
authors did not find any difference in the risk of malignancy between patients with PsA and 
RA and reported non- melanoma skin cancer to be the most common malignancy.  
2.6 Summary of The Literature Review  
The literature review is inconclusive and had shown inconsistency among authors. 
Some studies have reported an increased cancer risk (Askling et al., 2005; Bongartz et 
al.,2006; Beyaert et al., 2013; Y. Chen, Chang, Wang, & Wu, 2011; Smitten, Simon, 
Hochberg, & Suissa, 2008), others decreased or no risk (Dommasch et al., 2011; Haynes et 
al., 2013., Hellgren et al., 2014; Gross et al., 2014; Mercer et al., 2012; Wu et al 2014). As 
an example, randomized control trials were limited by short duration of follow up and 
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sparse adverse events data which are not powered enough to detect rare adverse events. 
Two meta-analysis of RCTs in the literature review of patients treated with TNF alpha 
inhibitors showed different results. Bongartz et al. (2006) reported that malignancies were 
significantly higher in patients treated with anti- TNF, OR of 3.3 (95% CI 1.2-9.1) where 
as (Dommasch et al., 2011) did not observe any significant increased cancer risk.  
Differences between the two study outcomes can be explained by the differences in the 
placebo- controlled phases duration included in the analysis. Studies chosen by Bongartz 
et al. (2006) had longer study phases (mean of 32.7, range 12-54 weeks) than those included 
in Dommasch et al. (2011) study (mean 17.8 range 12-30 weeks). Longer study phases 
could have led to an increased detection of events (especially if the risk increases over time) 
whereas, small number of events may affect the precision of risk estimate.  Furthermore, 
number of observational studies (Gross et al., 2014; Hellgren et al., 2014; Mercer et al., 
2015; Wu et al., 2014;) have relied on administrative data bases and national cancer 
registries for their study population. One disadvantage of this is that there may be 
malignancies that were not reported during the study visits by patients or health providers, 
leading to underascertainment. Misclassification bias can also occur with the use of 
administrative databases and can potentially lead to an under estimation of the associations. 
Follow-up times among observational studies ranged from 5 years to 35 years, whereas the 
sample size ranged from 399 to as high as 23,644. It is likely that the variability observed 
in the results may have resulted from these differences. Different patients geographic 
backgrounds is possibly another contributing factor to differences in study results. For 
instance, certain types of cancers can be more frequent in some geographic areas than 
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others. This may be due to difference in distribution of both known and unknown risk 
factors. 
2.7 Study Justification 
Our main study objective is to investigate Cancer Incidence in patients with 
Psoriatic (PsA) and Rheumatoid Arthritis (RA) and to examine the impact of chronic 
systemic inflammation as well as treatment on cancer formation in these groups of patients. 
Although PsA and RA are accounting only for 2% of the of the general population (PHAC, 
https://www.canada.ca/en/public-health/services)  they do  carry  a high burden of cost and 
disability such as: impaired physical function, reduced quality of life (QOL) and increased 
mortality Rahman et al. (2017). Despite some of the differences in their clinical 
presentation, we chose to combine both diseases in our investigation because of their two 
important shared similarities:  systemic chronic inflammation and the methods of treatment. 
These similarities have recently raised several questions and debates about the possibility 
of been linked to cancer formation (Kiraly, Gong, Olipitz, Muthupalani, & Engelward, 
2015) and (Askling et al., 2005; Bongartz et al., 2006). We also wanted to compare the 
cancer rates between these two diseases. Bonovas et al. (2016) similarly investigated the 
risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and 
ankylosing spondylitis. Although the reviewed literature is inconclusive, number of studies 
were found that showed an increased risk of cancer in PsA and RA patients (Askling et al., 
2005; Bongartz et al.,2006; Beyaert et al., 2013; Y. Chen, Chang, Wang, & Wu, 2011; 
Smitten, Simon, Hochberg, & Suissa, 2008).  The literature review also indicated that 
Newfoundland and Labrador has one of the highest cancer incidence rates (586.8 per 
100,000) when compared to other provinces (Canadian Cancer Statistics 
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(http://www.cancer.ca)). It also showed that the province has the highest rates for such 
cancers such as lung cancer in males (98.0/100,000), colorectal cancer for males and 
females (112.2/100,000 and 76.5/100,000 respectively), breast and cervical cancers in 
females (152.0/100,000 and 10.7/ 100,000 respectively), as well as prostate cancer in males 
(132.9/100,000). These high cancer rates are presumed to be associated with high 
prevalence of risk factors such as smoking 20% (Reid, Hammond, Rynard, & Burkhalter, 
2014), obesity 41.8% (Twells, Gregory, Reddigan, & Midodzi, 2014), unhealthy diet and, 
possibly, screening programs. For instance, the high colorectal cancer mortality rates in NL 
are presumed to be because of poor patient’s compliance with screening. Based on 2007 
data from the Canadian Community Health Survey Cycle 2.1, the proportion of people who 
reported Colorectal Cancer (CRC) screening among the four provinces (Ontario, British 
Columbia, Saskatchewan, and NL) was lowest in NL at 12.6%. Only 4% of women in NL 
reported taking a fecal occult blood test (FOBT) in the 2 years before the survey was 
conducted Green et. al. (2007). In addition, 2008 provincial screening rates for 
Newfoundland and British Columbia showed that up to 85.4% and 91.4% of residents had 
never been screened with FOBT and endoscopy, respectively (Sewitch, Fournier, Ciampi, 
& Dyachenko, 2008). Information on the prevalence and burden of PsA and RA in NL 
population is highly limited. The author was unable to find any study that investigated 
cancer incidence in these two diseases in NL population. However, the evidence found in 
the literature review was sufficient to make us speculate of a heightened cancer risk in our 
study population. Based on the aforementioned, we hypothesized that the cancer incidence 
in our study population is higher compared to the NL general population. 
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CHAPTER 3 
METHODOLOGY 
3.1 Study Design  
We conducted a retrospective study to examine cancer incidence in Psoriatic 
Arthritis (PsA) and Rheumatoid (RA) patients. A clinical chart review was conducted on 
patients who attended a local Dermatology and Rheumatology clinic in St. Johns, NL from 
2011-2014. Patients came from various parts of Newfoundland and Labrador. Clinical 
outcomes of interest were any type of new cancer and precancerous lesion documented in 
the study cohort from January - 1st 2011 to December 31st, 2014. Data collection began in 
December 2014 after receiving approval from the Health Research Ethics Authority 
(HREA). A total of 805 clinical charts of patients who attended the Rheumatology clinic 
from 2011-2014 were reviewed from a total of 2000 available charts (Fig.2) Of them, 235 
were PsA and 570 were RA patients. After exclusion of patients who did not meet inclusion 
criteria, 700 (200 PsA and 500 RA) patients were included in the final analysis.  De-
identified data was collected for the study purpose.  
3.1a) Eligibility Criteria 
      Inclusion Criteria: 
Adult patients with an established diagnosis of PsA or RA who attended the Rheumatology 
clinic from 2011-2014       
      Exclusion Criteria: 
Patients ≤19 years of age 
Those with previous history of malignancy 
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Those with a history of other autoimmune diseases such as Systemic Lupus Erythematous 
or Sjorgren’s syndrome 
Patients with skin disease other than Psoriasis 
Patients with a history of joint disease other than Psoriatic Arthritis or Rheumatoid Arthritis 
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Figure 3.1. Flow Chart of Study Subject Selection  
 
 
 
 
 
  
Flow Chart of Study Subject Selection (Figure 2) 
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3.2 Study Population 
Seven hundred adult patients (68.6% females) with established diagnoses of 
Psoriatic Arthritis (PsA) and Rheumatoid Arthritis (RA) were included in the study. 
Diagnosis of RA was made using Internationally Accepted Classification Criteria by the 
American College of Rheumatology (ACR, 2010). Diagnosis of PsA was established by 
using Classification Criteria for Psoriatic Arthritis (CASPAR) (Taylor et al., 2006). 
3.3 Research Questions 
Primary Research Question: 
Is the incidence of malignancy statistically significantly higher in patients diagnosed with 
PsA and RA compared to the NL general population? 
Secondary Research Questions:  
Is there a significant association between confirmed malignancy and disease severity? 
Is there a significant association between treatment modalities including Biologic Disease 
Modifiers (bDMARDs)? Is there a significant difference in cancer rates between these two 
types of inflammatory arthritis? 
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3.5 Sample Size Justification 
This was a retrospective chart review. The sample size justification was based on 
total number of clinical charts related to patients with PsA and RA from 2011-2014. The 
study site archives close to 2,000 active RA and PsA clinical charts and sees approximately 
250-300 new patients per year. At the time of data collection, we reviewed 805 clinical 
charts and found that 700 were eligible according to our inclusion criteria. 
We conducted a Post-hoc Power analysis (1- β is computed as a function of α, the 
population effect size, and N) using G-Power software 3.1 to determine whether our sample 
size was large enough to provide enough power to detect a meaningful effect. 
http://www.gpower.hhu.de/en.html  
A Post -Hoc analysis is performed after a study has been conducted so that the 
sample size N, is already a matter of fact  (Faul, Erdfelder, Buchner, & Lang, 2009). Given 
our study sample size N-700, α-0.05, and a specified effect size of 0.3 this type of analysis 
returned the power (95%), or the β error of 5%. 
 
3.6 Study Objectives 
The main objective of this study was to investigate the incidence rates of 
malignancies and precancerous lesions in adult patients with Psoriatic Arthritis and 
Rheumatoid Arthritis and compare our study findings to that of the general population of 
Newfoundland and Labrador. 
We also investigated the association between the documented malignancy and the disease 
severity and duration, as well as treatment modalities, including Biologic Disease Modifiers 
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(bDMARDs). Malignancy rates between these two cohorts of PsA and RA patients were 
also compared. 
3.7 Data Collection 
Data collection began in December 2014 until September 2016. All required 
information was retrieved from patients clinical charts and entered directly into a 
predefined SPSS database that contained relevant variables. The incidence of malignancy 
was evaluated in a cohort of 700 patients and compared to the data provided by Statistics 
Canada. Information was collected on: 1) patients demographics (age, sex, smoking status, 
duration of disease), 2) past medical history of comorbidities and 3) treatment modalities. 
We additionally retrieved information on patients disease activity and inflammation 
severity using disease activity measuring tools, clinical parameters and measurements 
makers. The above information was normally collected during patient’s 1st clinic visit as 
well as during yearly follow-up visits. Detailed descriptions of questioners are included in 
the appendix. Patients disease activity was evaluated using predefined questionnaires such 
as 1) The 28-joint disease activity score (DAS28) [an established and validated tool that is 
used to determine both disease activity and treatment response in both PsA and RA patients 
(Salaffi et al., 2014)]. The scores provide ranges that corresponds to high, moderate, and 
low disease activity. High disease activity relates to DAS28 >5.1, moderate to DAS28 of 
>3.2 to 5.1, low disease activity is regarded in the range of 2.6 to 3.2. 3, 2) Psoriatic Arthritis 
Screening Questionnaire (PASQ) is a sensitive and specific self-administered tool used for 
the diagnosis of Psoriatic Arthritis and to measure the degree of inflammatory symptoms. 
The PASQ consist of a questionnaire (with a maximum score of 10) and a diagram with a 
(maximum score of 5) indicating where patients experienced joint swelling or pain 
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(Khraishi et.al., 2010) and 3) Health Assessment Questionnaire (HAQ) which is an 
instrument designed to assess patients disability, discomfort, medication side effects, costs, 
and mortality (Smolen & Aletaha., 2012). Each question is answered on a four-level scale 
of impairment ranging from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much 
difficulty; and 3 = inability to do activity of daily living. Severity of inflammation was 
additionally evaluated using clinical parameters and measurements makers such as: 1) 
Tender Joint Count (TJC), 2) Swollen Joint Count (SJC 1), 3) C-reactive protein (CRP) 
[normal range values <10 mg/l], and 2) Erythrocyte Sedimentation Rate (ESR) [normal 
range values females < 20 mm/hr, males<15mm//hr]. Cancer diagnosis was ascertained 
from patients medical records using the International Classification of Diseases (ICD-10) 
codes to define malignancies. 
3.8 Statistical Analysis 
The main study outcome was any newly diagnosed and documented cancer during 
the study period. All statistical analyses were performed using SPSS version 21.0 for 
Windows (IBM Inc.) Descriptive statistics included means (SD) and proportions when 
appropriate. The difference between groups (PsA vs. RA) was examined using Chi Square 
test for categorical variables and t-test for continuous variables. Binary logistic regression 
analysis (Univariate and Multivariate) was carried out to assess potential association 
between the binary outcomes (cancer 1-yes, 0-no) and explanatory variables (clinical 
parameters, laboratory markers and set of treatments with biologics). Potential confounding 
risk factors included in the logistic models were age, sex, obesity, smoking status and 
disease duration. Amongst confounders, only age was a significant predictor of 
malignancy. Unadjusted and adjusted binary logistics Odds Ratios (ORs), and 95% 
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confidence intervals (95% CI) for all cancers were calculated. Cancer Incidence was 
measured by both Incidence rate (person-time rate) and Incidence proportion rate. Age 
Standardized Incidence Rates (ASIR) stratified by sex were used to evaluate overall cancer 
risk and proportion rates for measuring and comparing cancer rates between the two 
cohorts.  Newfoundland and Labrador general population rates were taken from Statistics 
Canada (http://www5.statcan.gc.ca/cansim). Person-years for each participant were 
calculated amongst patients with established PsA/RA diagnosis to the date of cancer 
diagnosis or the end of study period. The minimum level of statistical significance was a 
priori defined at 5%, all tests were two-tailed. Incidence rates or person-time is a measure 
of incidence that incorporates time directly into the denominator and describes how quickly 
disease occurs in a population https://www.cdc.gov. We chose to calculate age incidence 
rates because person- time can accommodate persons coming and leaving the study such 
as those who died or were lost to follow up (Tables 4.6 and 4.7). We adjusted our analysis 
by age and since our cohort was significantly dominated by females (who were more obese 
than males), we further stratified by sex to help adjust for weight and sex effect. 
Newfoundland and Labrador general population rates were taken from Statistics Canada 
(http://www5.statcan.gc.ca/cansim). A person-time rate was calculated from our cohort 
where our study participants were observed, and occurrence of new cancer cases were 
documented. Person-years for each participant were calculated amongst patients with 
established PsA/RA diagnosis to the date of cancer diagnosis, lost to follow up, death or 
the end of study period.  The ASIR was obtained by dividing the number of new of cancer 
cases during specified period by the total time each person was observed during the study 
period. 
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CHAPTER 4 
STUDY RESULTS 
4.1 Patient’s Demographics 
Seven hundred patients were included in the analysis. Demographics, clinical and 
laboratory characteristics for the total population and by PsA and RA cohorts are 
summarized in Tables 4.1 and 4.2. The study population was normally distributed by age 
and skewed by sex with more patients being female (68.6 vs 31.4; P= <0.001).  The 
youngest study participant was 21 years of age and the oldest 96. The overall mean (SD) 
age of participants was 58.4 (12.28) and age at diagnosis of disease was 46.8 (12.88). Three 
hundred and seventy patients (52.9%) had a history of obesity (BMI>29) and 147 (21.0%) 
reported having smoked. Females were significantly more obese than males (34.2% vs 
18.7%; P=0.018), had higher ESR scores (24.18 vs 19.63; P=0.007), [normal range values 
females <10mm/hr, males<6mm/hr] and were more likely to be exposed to 
Hydroxychloroquine (42.7% vs 12.1%; P=<0.001). However, men showed longer 
treatment duration with DMARDs (MTX) (4.65 vs 3.85; P=0.002). 
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 Table. 4.1 Demographic and Clinical Characteristics for the Cohort (N=700) 
Characteristics Total Females, N (%) Males, N (%) P* (95%CI) 
Gender (Females) 700 (100) 480 (68.6) 220 (31.4) <0.001(0.78-.0.94) 
Age mean (SD) 58.4 (12.28) 58.42 (12.6) 58.60 (11.46) 0.859 (-1.78-2.14) 
Age at diagnosis of disease, 
mean (SD) 
46.83 (12.88) 46.81(13.30) 46.89 (11.93) 0.941 (-1.98-2.1) 
Duration (years) disease 
symptoms, mean (SD) 
11.59 (8.38) 11.56 (8.49) 11.66 (8.15) 0.876 (-1.23-1.44) 
Smoking 147 (21.0) 102 (14.6) 45 (6.4) 0.842 (0.70-1.55) 
Obesity (BMI > 30) 370 (52.9) 239 (34.2) 131(18.7) 0.018 (0.49-0.93) 
PASQ score, mean (SD) 
(PsA patients only) 
4.52 (2.34) 4.85(3.63) 4.20 (2.16) 0.042 (0.02-1.27) 
DAS28, mean (SD) 3.65 (1.23) 3.68 (1.24) 3.61 (1.23) 0.503 (-26-0.13) 
C-Reactive Protein (CRP), 
mean (SD) 
10.0 (19.80) 10.28 (21.04) 9.52 (16.76) 0.637 (0.39-2.40) 
ESR, mean (SD) 22.75 (20.71) 24.18 (20.35) 19.63 (21.00) 0.007 (-7.84- 1.89) 
Total Tender Joint Counts, 
mean (SD) 
 
8.43(8.1) 8.69 (9.23) 7.85 (8.12) 0.246 (-2.26-0.58) 
Total Swollen Joint Counts, 
mean (SD) 
3.20 (3.73) 3.13 (3.35) 3.35 (3.51) 0.458 (-37-0.82) 
HAQ score, mean (SD) 0.94 (1.64) 0.95 (0.74) 0.92 (2.71) 0.827 (0.29-0.23) 
Exposure to Bios 366 (52.3) 245 (35.0) 121 (17.3) 0.370 (0.61-1.17) 
Exposure to MTX  615 (87.9) 421 (60.1) 150 (27.7) 0.907 (0.60-1.51) 
Exposure to Bios and MTX,  331(47.3) 227 (32.4) 104 (14.9) 0.996 (0.72-1.37) 
Treatment Duration with Bios, 
mean, (SD) 
2.72 (3.64) 2.58 (2.94) 3.01 (3.21) 0.082 (-.055-0.91) 
Treatment Duration MTX, 
mean, (SD) 
4.1(3.11) 3.85 (2.8) 4.65 (3.55) 0.002(-1.29-  -0.30) 
Exposure to Corticosteroids 287 (41.0) 199 (41.5) 88 (40.0)  0.741 (0.76-1.47) 
Exposure to 
Hydroxychloroquine 
(CHQ) 
384 (54.9) 229 (42.7) 85 (12.1) <0.001(1.89-3.64) 
Exposure to NSAIDs 650 (92.9) 444 (63.4) 206 (29.4) 0.717 (0.82-1.83) 
Exposure to Sulfasalazine 
(SSZ) 
117 (16.7) 81 (11.6) 36 (5.1) 0.913 (0.67-1.59) 
*Chi square p for categorical variables and t-test p for continuous variables (Fisher’s Exact p when cell 
count is less than 5)  
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4.2 Study Population Comparison by PsA and RA Cohort 
Among the 700 subjects, 200 (28.6%) were diagnosed with PsA and 500 (71.4%) 
were diagnosed with RA. Patients’ mean age at the time of data collection were (54.7 vs 
59.9 vs; P<0.001) respectively. Since we aimed to examine the effect of duration of disease 
on the risk of cancer, we also collected data regarding arthritis onset. Patients’ mean age at 
the time of PsA and RA diagnosis was not significantly different. The study groups were 
predominantly female 480 (68.6%). As expected in the RA cohort, the proportion of 
females 378 (54.0%) was significantly greater than the proportion of males 122 (17.4%), 
and so was the proportion of females between the two cohorts 378 (54.0%) vs 102 (14.6%); 
P= <0.001. Whereas, the number of males and females in the PsA cohort were equally 
distributed 98(14.0%) vs 102 (14.6%). For most part, both cohorts did not differ 
significantly by their characteristics; however, PsA patients were younger (54.7 vs 59.9; 
P<0.001) and had shorter disease duration (8.59 vs 12.78; P<0.001) than those with RA. In 
addition to assessing factors such as age, sex, smoking status etc., disease activity measures 
for PsA and RA (DAS28, PASQ, CRP, ESR, HAQ, TJC and SJC) were also evaluated. 
Even though at the time of analysis there were no overall significant differences in the 
disease activity scores between the two cohorts (P=0.610), patients with RA showed 
significantly higher disease activity as indicated by a higher mean score for CRP= (11.18 
vs 7.19; P=0.016) [normal range values<10mg/l], ESR= (24.7 vs 17.7; P<0.001) [normal 
range values females < 20 mm/hr, males <15 mm/hr] scores, and number of total swollen 
joint counts TSJC= (3.41 vs 2.69; P=0.021). The Mean (SD) score for the Psoriasis and 
Arthritis Severity Questionnaire (PASQ) for patients with Psoriatic Arthritis was 9.75. The 
PASQ consist of a questionnaire (with a maximum score of 10) and a diagram with a 
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(maximum score of 5) with a maximum combined score of 15 indicating the severity of the 
disease.  
With respect to treatment exposure, both study groups had similar exposure to most 
treatment, although RA patients were more likely to be exposed to Methotrexate, 469 
(67.0%) vs 146 (20.9%), Corticosteroids 255 (36.4%) vs 32 (4.6%) and 
Hydroxychloroquine 362 (51.7%) vs 22 (3.1%). Both groups showed similar exposure to 
combination therapy (Biologics and MTX). 
Table 4.2 shows comparison of demographics, clinical and laboratory 
characteristics between RA and PsA cohorts.  
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Table 4.2 Comparison of Demographics, Clinical and Laboratory Characteristics Between 
                                         RA (N=500) and PsA (N=200) Cohorts 
Characteristics Total N (%) 
RA Cohort 
N (%) 
PsA Cohort 
N (%) 
P* (95% CI) 
Number of patients 700 (100.0) 500 (71.4) 200 (28.6) ---------- 
Gender (Females) 480 (68.6) 378 (54.0) 102 (14.6) <0.001 
Age in years, mean (SD) 58.5 (12.27) 59.98 (12.47) 54.72 (10.93) <0.001 (3.28-7.24) 
Age at diagnosis of disease, 
mean (SD) 
46.8 (12.8) 47.12 (13.37) 46.13 (11.57) 0.358 (-1.12-3.10) 
Duration (years) disease 
symptoms, mean (SD) 
11.58 (8.38) 12.78 (8.24) 8.59 (7.98) <0.001 (2.84-5.53) 
Smoking 147 (21.0) 108 (15.4) 39 (5.6) 0.608 (0.58-1.32) 
Obesity (BMI >30) 370 (52.9) 259 (37.1) 111(15.9) 0.403 (0.83-1.60) 
PASQ score, mean (SD)  -------------- 4.52 (2.34) --------- 
DAS28, mean (SD) 3.65 (1.23) 3.64 (1.23) 3.69 (1.22) 0.610 (-0.25-0.15) 
C-Reactive Protein (CRP), 
mean (SD) 
10.0 (19.78) 11.18 (22.58) 7.19 (9.20) 0.016 (0.75-7.22) 
ESR, mean (SD) 22.75 (20.71) 24.76 (20.58) 17.72(20.22) <0.001 (3.67-10.40) 
Total Tender Joint Counts, 
mean (SD) 
8.43 (8.90) 8.62 (9.13) 7.96 (8.28) 0.375 (-80-2.12) 
Total Swollen Joint Counts, 
mean (SD) 
3.20 (3.73) 3.41(3.82) 2.69 (3.45) 0.021 (0.11-1.13) 
HAQ score, mean (SD) 0.94 (1.64) 1.01(1.89) 0.77(0.63) 0.076 (-0.25-0.51) 
Exposure to Bios  366 (52.3) 225 (36.4) 111 (15.9) 0.315 (0.86-1.66) 
Exposure to MTX 615 (87.9) 469 (67.0) 146 (20.9) <0.001(0.08-0.20) 
Exposure to Bios and MTX 331 (47.3) 224 (34.9) 87 (12.4) 0.210 (0.58-1.12) 
Treatment Duration with Bios, 
mean, (SD) 
2.72 (3.03) 2.68(3.01) 2.82 (3.09) 0.577 (-0.64-0.35) 
Treatment Duration MTX, 
mean, (SD) 
4.10 (3.11) 4.08(2.79) 4.17(3.81) 0.725 (-0.60-0.42) 
Treatment Duration Bios and 
MTX 
2.72 (3.03) 2.68 (3.01) 2.82 (3.09) 0.577 (-0.64-0.35) 
Exposure to Glucocorticoids 287 (41.0) 225 (36.4) 32 (4.6) <0.001(0.12-0.27) 
Exposure to Sulfasalazine 
(SSZ) 
117(16.7) 61(8.7) 56 (8.0) < 0.001 (1.86-4.21) 
Hydroxychloroquine 
(CHQ) 
384 (54.9) 362 (51.7) 22(3.1) < 0.001(0.29-0.07) 
 
*Chi square p for categorical variables and t-test p for continuous variables (Fisher’s Exact p when cell 
count is less than 5)  
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4.3 Cancer Occurrence 
       A total of 37 (5.3%) different types of cancers were diagnosed during the study period. 
Among those affected, 13 (31.4%) were in males and 24 (64.9 %) were in females. Cancer 
patients were significantly older (65.38 vs 58.10) P= <0.001 and had a higher ESR score 
(30.21 vs 22.33) P= 0.024. One male patient had multiple cancers at different time periods 
(Skin cancer in 2011 and Lung cancer in 2013). There were nine (24.3 %) in the PsA group 
and 28 (75.7%) cases diagnosed in the RA group (Table 4.3). Ten (27 %) patients diagnosed 
with cancer were smokers. Eight (21.6%) cancers were diagnosed in the first year, nine 
(24.3%) in the second year, four (10.8%) in the third, and sixteen (43.2%) in the fourth year 
of the study. Two patients were lost to follow up (one died by the first year and another 
after three years). Both patients deaths were due to cancer related causes.  
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Table 4.2 b) Comparison of Demographics, Clinical and Laboratory Characteristics Between 
                                          Cancer N= 37 and Non-Cancer Patients N= 663  
Characteristics Total N (%) 
Patients with   
Cancer 
N (%) 
Patients 
without 
Cancer 
N (%) 
P* (95% CI) 
Number of patients 700 (100.0) 37 (5.3) 663 (94.7) ---------- 
Gender (Females) 480 (68.6) 24 (64.9)     456 (68.8) 0.591(0.58-1.33) 
Age in years, mean (SD) 58.5 (12.27) 65.38 (10.66)  58.10 (12.25) <0.001 (3.24-10.95) 
Age at diagnosis of disease, 
mean (SD) 
46.8 (12.8) 51.54 (12.59) 46.57 (12.85) 0.022 (1.21-2.32) 
Duration (years) disease 
symptoms, mean (SD) 
11.58 (8.38) 13.78 (9.82) 11.46 (8.28) 0.102 (-0.45-5.09) 
Smoking 147 (21.0) 10 (27.0) 137 (20.7) 0.405 (0.64-1.84) 
Obesity (BMI >30) 370 (52.9) 16 (43.2) 354 (53.5) 0.240 (0.76-7.22) 
DAS28, mean (SD) 3.65 (1.23) 3.76 (1.22) 3.65 (1.23) 0.576 (-0.30-0.53) 
C-Reactive Protein (CRP), 
mean (SD) 
10.0 (19.78) 8.34 (10.79) 10.13 (20.17) 0.592 (-8.36-4.77) 
ESR, mean (SD) 22.75 (20.71) 30.21 (23.40) 22.33 (20.49) 0.024 (1.03-14.7) 
Total Tender Joint Counts, 
mean (SD) 
8.43 (8.90) 7.65 (8.56) 8.46 (8.92) 0.585 (-3.77-2.13) 
Total Swollen Joint Counts, 
mean (SD) 
3.20 (3.73) 2.70 (2.48) 3.23 (3.78) 0.405 (-1.76-0.712) 
HAQ score, mean (SD) 0.94 (1.64) 1.01(0.83) 0.94 (1.67) 0.638 (-0.23-0.37) 
Exposure to Bios  366 (52.3) 16 (43.2) 350 (52.8) 0.311 (-1.12-3.14) 
Exposure to MTX 615 (87.9) 35 (94.6) 580 (94.3) 0.299 (0.76-1.55) 
Exposure to Bios and MTX 331 (47.3) 12 (32.4) 319 (48.1) 0.089 (0.55-1.33) 
Treatment Duration with Bios, 
mean, (SD) 
2.72 (3.03) 2.43 (3.22) 2.73 (3.028) 0.702 (-0.98-1.45) 
Treatment Duration MTX, 
mean, (SD) 
4.10 (3.11) 4.32 (3.59) 4.09 (3.09) 0.659 (-0.80-1.26) 
Exposure to Glucocorticoids 287 (41.0) 18 (48.6) 269 (40.6) 0.391 (0.54-3.21) 
Exposure to Sulfasalazine 
(SSZ) 
117(16.7) 6 (16.2) 111 (16.7) 0.098 (-0.62-1.39) 
Hydroxychloroquine 
(CHQ) 
384 (54.9) 18 (48.6) 366 (55.2) 0.498 (0.66-1.54) 
 
*Chi square p for categorical variables and t-test p for continuous variables (Fisher’s Exact p when cell 
count is less than 5)  
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Chart 4.3  
 
 
RA males showed a higher proportion of cancers (7.4 %) compared to the rest of 
the cohort. There was no difference in the percentage distribution of cancers between male 
and female patients in the PsA cohort (4.1% vs 4.9 %). The proportion distribution of 
cancers between the two cohorts was not significantly different (P=0.709). One Psoriatic 
Arthritis male patient had multiple cancers at different time periods (Skin cancer in 2011 
and Lung cancer in 2013). There were 34 (91.9 %) solid and 3 (8.1 %) hematologic cancers 
(Table 4.3). All cases were histologically confirmed. The most common solid tumors were 
Breast and Skin cancers (eight (21.6% each), followed by five Bowel and Lung cancers in 
equal proportion (13.5%). Of those eight Skin cancers, five were Melanomas (two basal 
cell carcinomas (BCC), three squamous cell carcinomas (SCC)) and three Non-Melanomas. 
There were three Prostate and three Thyroid cancers (8.1% each). Hematologic 
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malignancies were represented by one Myeloblastic leukemia (2.7%) and two Non-
Hodgkin lymphomas (NHL) (5.4%).  
 
Table 4.3 Most Common Types of Cancers and Precancerous Lesions 
by RA and PsA Cohort (%) N=37 
Characteristics 
Malignancies (ICD-10 code) 
Total, N (%) RA, N (%)  PsA, N (%) 
Most Common Solid Cancers: 32 (86.5) 25(67.6) 7 (18.9) 
Bowel Cancer (C7A.02) 5 (13.5) 5 (13.5) 0 (0.0) 
Breast Cancer (C50.0) 8 (21.6) 6 (16.2) 2 (5.4) 
Prostate Cancer (C61.0)      3 (8.1) 2 (5.4) 1 (2.7) 
Skin Cancer (C43-C44) 8 (21.6)      7 (18.9) 1 (2.7) 
Lung Cancer (C34.0) 5 (13.5) 2 (5.4) 3 (8.1) 
Thyroid Cancer (C73.0)      3 (8.1) 3 (8.1) 0 (0.0) 
Other Solid Cancers: 
Renal, Bladder (C67.9-C68.9)           
Pancreatic Cancer (C 25.9)  
     2 (5.4) 
1 (2.7) 
1 (2.7) 
1 (2.7) 
1 (2.7) 
0 (0.0) 
1(2.7) 
       0 (0.0) 
      1 (2.7) 
Hematologic Cancers 
 (C85.9-C 92.0) 
Non-Hodgkin’s (NHL) 
Lymphoma and Myeloblastic 
Leukemia 
3 (8.1) 
2 (5.4) 
1(2.7) 
2 (5.4) 
2 (5.4) 
0 (0.0) 
1 (2.7) 
0 (0.0) 
1(2.7) 
Total # of Incident Cancers 37 (5.3)     28 (75.7)        9 (24.3) 
Pre-Cancerous Lesions  
Oral (K00-14) &Skin(L57.0) 
Buccal Mucosa    
Actinic Keratosis  
Cervical (N87.9) 
5 (0.7) 
1(20.0) 
1(20.0) 
3 (60.0) 
4 (80.0) 
1 (20.0) 
0 (0.0)      
3 (60.0)            
    
1(20.0) 
       0(0.0) 
      1(20.0) 
    0(0.0) 
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        Rheumatoid Arthritis (RA) female patients showed the highest proportions for Breast 
(16.2%), Skin (10.8%) and Thyroid (8.1%) cancers.  All two Lymphomas, as well as three 
Thyroid cancers, were also diagnosed only in the RA female population. Both genders in 
the RA cohort demonstrated higher proportions for Bowel cancer compared to the PsA 
cohort. RA male patients showed significantly higher promotion for prostate cancer 
compared to PsA males (5.4 vs 2.7%) P=0.031. A total of 5 (0.7%) precancerous lesions 
were identified in our study population, with 2 (40%) in men (one of the buccal mucosae 
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and one skin) and 3 (60%) in females (3 cervical dysplasias). Distribution of pre-cancerous 
lesions between the two cohorts were not significantly different (P=0.670).  
4.4 Treatment Characteristics and Comparison of Cancer Risk 
With respect to treatment, more than half of our study population 52.3% had a 
history of exposure to Biologics. Eighty seven percent of the population had a history of 
being treated with synthetic DMARDs (mainly MTX) and 47.3% percent had combination 
therapy with both types of drugs (Biologics and DMARDs (MTX)) (Table 4.1). Table 4.4 
compares the overall cancer risk with exposure to various treatment modalities and by PsA 
and RA cohorts. The overall cancer risk was significantly reduced in patients who were 
exposed to combination therapy for both Biologics and Methotrexate (OR= 0.3, 95% CI, 
0.02-0.44, P = 0.003). Etanercept similarly showed lower risk of cancer in RA patients as 
compared to other biologics (OR= 0.1, 95% CI 0.01-0.89 P=0.039). Adalimumab showed 
a non-significant overall cancer risk (P=0.053), whereas Rituximab showed overall non-
significant increased risk (P=0.203) in the RA cohort. Many traditional DMARDs (Mtx, 
SSZ, and HCQ) were numerically protective in RA and increased cancer risk in PsA 
patients. However, none of this were statistically significant and had wide CI’s. This can 
be explained by the rarity of events in our study (smaller number of patients and smaller 
number of incident cancers in PsA N= 200, cancers N= 9, vs RA N=500, cancers N=28) 
and short duration of follow-up. This numerical differences in risk shows how small 
numbers of can change results. Similarly, Sulfasalazine, P= 0.894, CHQ, P=0.257 and 
NSAIDs, P=0.070 showed protective effect against cancer but did not reach statistical 
significance. 
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Table 4.4 Comparison of Overall Cancer Risk and Exposure to Treatment 
Modalities: RA vs. PsA 
 
Exposure to 
Treatment 
      Overall                RA              PsA  
 
Biologics 
 
OR (95%CI) 
P  
Value* 
 
OR (95%CI) 
 
P 
value* 
 
OR (95%CI) 
 
P 
value* 
         
 
 
Adalimumab 2.9 (0.98 - 8.60) 0.053 
 
3.5 (0.48-24.95) 0.214 4.4 (0.56-39.50) 0.153 
Abatacept 1.4 (0.41-4.95) 0.570 1.4 (0.41-4.95) 0.570 ----------  
 
Etanercept 0.2 (0.33-1.95) 0.187 0.1 (0.01-0.89) 0.039* 0.6 (0.07-6.16) 
 
0.728 
Rituximab 1.9 (0.70-5.24) 0.203 1.9 (0.70-5.24) 0.203 ----------  
 
------- 
DMARDs:   
 
    
Methotrexate 1.1(0.34-2.98) 
 
0.980 0.5 (0.12-2.65) 0.477 1.6 (0.31-8.51) 0.559 
Sulfasalazine 0.8 (0.33-2.39) 0.894 0.5 (0.11-2.49) 0.425 1.7 (0.37-8.09) 
 
0.310 
Hydroxychloroquine 0.6 (0.32-1.35) 0.257 0.6 (0.28-1.47) 0.301 2.8 (0.41-19.43) 
 
0.162 
MTX + Biologics 0.3 (0.02-0.44) 0.003* 0.2 (0.03-0.35) 0.002* 0.5 (0.78-4.12) 
 
0.842 
Other Treatment:      
 
 
NSAIDs 0.3 (0.13-1.08) 0.070 0.7 (0.07-8.09) 0.843 0.7 (0.77-8.09) 
 
0.843 
Prednisone 1.3 (0.16-2.17) 0.388 1.6 (0.70-3.66) 0.261 0.8 (0.07-9.41) 0.885 
 
 
OR=ODDs Ratio; 95% CI=95% confidence interval  
*P= P Value= significant 
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Chart 4.6 
 
 
 Next, we examined the distribution of incident cancers by patients exposure to biologic 
type. The diagram below demonstrates that all Lymphomas and Breast cancers were 
diagnosed among patients who had a history of treatment with Rituximab.  Patients 
diagnosed with Skin and Breast cancers had multiple exposures, at various times to 
different types of biologics (Rituximab and Abatacept). Prostate, Thyroid, Lung and 
Bowel cancers occurred only in patients exposed to Adalimumab. The only patient with 
Myeloblastic Leukemia was exposed to Etanercept. None of the cancer patients were 
exposed to Golimumab or Infliximab.  
          In this study, we did not observe any statistically significant association 
between the studied inflammatory factors and cancer including DAS 28 and duration of 
disease. Table 4.5. 
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Table 4.5 Comparison of Cancer Risk between Disease Activity Parameters and   
Cancer 
*OR=ODDs Ratio; 95% CI=95% confidence interval  
*P= P Value= significant 
 
4.5 Calculations of Cancer Incidence Rate (IRs) / Person-time Rate (PYs) 
Incidence rates or person-time is a measure of incidence that incorporates time 
directly into the denominator and describes how quickly disease occurs in a population 
https://www.cdc.gov . We chose to calculate age incidence rates because person-time can 
accommodate persons coming and leaving the study such as those who died or were lost to 
follow up (Tables 4.6 and 4.7). We adjusted our analysis by age and since our cohort was 
significantly dominated by females (who were more obese than males), we further stratified 
by sex to help adjust for weight and sex effect. Newfoundland and Labrador general 
              Overall                RA              PsA  
 
Disease Activity 
    Parameters  
 
OR (95%CI) 
P  
Value* 
 
OR (95%CI) 
 
P value* 
 
OR (95%CI) 
 
P value* 
TSJC 
. 
0.8 (0.79-0.99) 
 
0.048 
 
0.8 (0.75-1.02) 
 
0.093 
 
0.4 (0.18-1.11) 
 
0.086 
CRP 
 
0.9 (0.94-1.01) 
 
0.256 
 
0.9 (0.84-0.99) 
 
0.027 
 
1.1 (0.94-1.41) 
 
 
0.167 
                ESR 
 
1.0 (0.99-1.03) 
 
0.169 
 
 
1.0 (0.99-1.05) 
 
0.111 
 
1.0 (0.90-1.12) 
 
 
0.895 
DAS28 1.2 (0.85-1.89) 0.233 1.2 (0.77-1.91) 0.384 2.4 (0.54-10.57) 0.246 
HAQ 
RF 
Disease 
Duration               
 
0.9 (0.77-1.22) 
1.0 (0.81-1.24) 
 
1.0 (0.97-1.05)    
 
0.842 
0.943 
 
0.509 
 
0.9 (0.77-1.17) 
1.0 (0.82-1.24) 
 
1.0 (0.98-1.07)   
 
0.646 
0.898 
 
0.221 
 
 
1.4 (0.99-21.93) 
0.9 (0.34-2.34) 
 
0.9 (0.84-1.05)  
 
 
0.780 
0.834 
 
0.272 
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population rates were taken from Statistics Canada (http://www5.statcan.gc.ca/cansim). A 
person-time rate was calculated from our cohort where our study participants were 
observed, and occurrence of new cancer cases were documented. Person-years for each 
participant were calculated amongst patients with established PsA/RA diagnosis to the date 
of cancer diagnosis, lost to follow up, death or the end of study period.   
Table 4.6 Age Standardized Cancer Incidence Rate (ASIR) / Person-Time Rate (PYs)/100,000 
(Females) 
 
 
Table 4.7 Age Standardized Cancer Incidence Rate (ASIR) / Person-Time Rate (PYs)/100,000 (Males) 
 
 
 
Age Groups Cancer Cases, 
Study 
Population 
Person -time 
Rate (PYs) 
Study 
Population 
Standard 
Population 
Cancer 
Cases 
Standard 
Population 
20-29 0 48 12 30,659 20 
30-39 0 92 23 32,981 55 
40-49 0 304             76 39,490 135 
50-59 8 529 134 43,078 300 
60-69 10            561 144 38,070 525 
70-79 13 261 70 20,425 395 
80+ 2 64.5 21 11,616 230 
Total 24 1,859 480 216,319 1,660 
Age Groups Cancer Cases,  
Study 
Population 
Person -time 
Rate (PYs) 
Study 
Population 
Standard 
Population 
Cancer 
Cases 
Standard 
Population 
20-29 0 8 2 31,547 10 
30-39 0 40 10 31,525 25 
40-49 2 142             36 37,926 65 
50-59 3 266 68 42,687 305 
60-69 5           280 72 37,257 660 
70-79 3 98 26 18,684 535 
80+ 0 24 6 7,529 230 
Total 13 858            220 207,155 1,830 
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              Study Rate: ASIR/(PYs) 1 = 10.07 (6.46,13.68)/ 100,000                                
           General Population (NL) Rate: ASIR/(PYs) 2 = 8.24 (7.97-,8.51)/100,000 
           ASIR1-ASIR 2= 1.83 (-1.79, 5.44)/100,000, P=0.3217  
There is no difference in the cancer rate between our study and the NL general population. 
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CHAPTER 5 
DISCUSSION 
 
5.1 Discussion of the Study Results 
In this retrospective study, we investigated the incidence of malignancy among 700 
patients diagnosed with Psoriatic and Rheumatoid Arthritis and compared our incidence 
rate to the incidence rate of cancer in the NL general population. 
 Inflammatory Arthritis is reported to be the third most common chronic condition 
in adults in NL (25.4%) (http://www.statcan.gc.ca/tables-tableaux/sum-
som/l01/cst01/health52b). The province also continues to have the highest cancer incidence 
rates per capita in the country (586.8/100,000) with 3,900 new cases annually); 
http://www.cancer.ca/en/cancer. Despite these facts, there is a paucity of published 
information on the incidence of malignancy in this population in Newfoundland and 
Labrador. We were not able to find studies that compared the risk of malignancy between 
these two Immune Mediated Diseases: Psoriatic Arthritis and Rheumatoid Arthritis and the 
Newfoundland and Labrador general population. To our knowledge this is the first 
epidemiological study of this kind in NL.          
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Graph 5.1 
 
         
 During this four-year study period of 200 PsA (28.6%) and 500 RA (71.4%) 
patients, several key observations were made. We did not find any significant difference in 
the cancer rate between our study and the NL general population (P= 0.3217). Our findings 
are consistent with prior published studies.  In 2014, Fagerli  and colleagues used the British 
Society for Rheumatology Biologics Register (BSRBR) to investigate the risk of cancer in 
709 Psoriatic Arthritis patients treated with TNFi. Their study findings suggested that there 
was no overall increased risk of malignancy compared with the general population. 
Although, a significant increased incidence for non-melanoma skin cancer (NMSC) was 
reported in their study. Similarly, in 2008, Lydia Abasolo and colleagues used the 
EMECAR cohort to investigate the incidence of cancer in 789 RA patients from Spain. The 
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hematopoietic (SIR=5.4, CI,1.1-15.7) and lung cancers (SIR =3.5, CI,1.4-7.1). In 2016, in 
a longitudinal cohort study of 8,439 PsA patients, Hagberg et al. used the Clinical Practice 
UK Research Datalink to assess the incidence of solid and hematologic cancers. The study 
findings showed similar cancer rates of solid and nonmelanoma skin cancers in patients 
with PsA compared with non PsA patients. However, the rates of hematologic cancer in 
their study were significantly higher in the PsA cohort (P=0.011). In Canada, Cibere, 
Sibley, & Haga (1997) conducted a 35-year prospective study of RA patients (n=862) to 
determine the relative risk of malignancy. The authors reported the incidence rates for non-
Hodgkin’s lymphoma and all other site-specific malignancies not to be significantly 
different from the general population. 
A total of 37 malignancies were documented in our study. Of these, 34 (91.9%) 
were solid cancers and 3 (8.1%) were hematologic cancers. The most commonly observed 
cancers were Skin and Breast cancers (21.6% each), followed by Bowel and Lung cancers 
(13.5% each). Two Lymphomas and three Thyroid cancer cases were documented in our 
RA female population. One case of Myeloblastic Leukemia was reported among males in 
the PsA cohort. These findings reflect the data from the Canadian Cancer Statistics (2015), 
reporting Breast cancer being the leading cancer in women in NL (http://www.cancer.ca). 
Rohekar et al. (2008), in a 26-year prospective cohort to determine the prevalence of 
malignancy in PsA patients, reported that the incidence of malignancy in their study did 
not differ from that in the general population. The most frequent types of cancer in this 
study were breast, lung, and prostate cancers. In a 5-year retrospective single center study 
of 399 patients, Fanto et al. (2015) evaluated the risk of malignancy in 399 patients with 
Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis. The overall cancer 
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risk in this study was not significantly increased compared to the general population. 
However, RA females undergoing immunosuppressive therapy had a significantly 
heightened risk of hematologic malignancies than expected (SIR = 6.9, 95% CI, 1.88-
17.66). Our study findings do differ from other studies that have reported an increased 
cancer risk in their study population. For instance, in the reviewed literature Chen et al. 
(2011) observed 935 cancers in patients with RA. Their study results showed that patients 
with RA had a significant increased risk of cancer (SIR= 2.74, 95% CI, 2.68–2.81). Among 
hematologic cancers, the risk of non-Hodgkin's lymphoma was greatest (SIR= 3.54, 95% 
CI, 3.45–3.63). Such differences in results between their study and ours could be explained 
by several factors. The Chen et.al. (2011) study had a longer duration of follow up 
compared to ours (11years vs 4 years) allowing more time for a rare event such as cancer 
to occur. The larger sample size of 23,644 vs 700 patients in our study gave their study 
more power to detect differences between groups. However, their study was also limited 
by an inadequate adjustment for important prognostic factors that might have likely 
impacted the validity of their results. Several important confounding factors such as 
smoking, alcohol use and body mass index were not adjusted for. The authors of this  study 
also relied on the nation database for patients recruitments, which could have allowed for 
misclassification bias to occur.  
There was no significant difference in the proportion of incident cancers between 
our PsA and RA patients (P=0.709). In 2014, Gross et al. reported similar findings. In their 
observational study of 2,970 patients with PsA and 19,260 patients with RA, authors 
reported similar cancer rates between their cohorts (P= 0.864). Just like in our study, Skin 
cancer was also reported to be the most common cancer in their cohort. Whilst there was 
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an equal distribution of Lymphoma between the two cohorts in this study (P=0.668), we 
reported Lymphoma only among RA female patients. Differences in our findings can 
possibly be explained by the larger and diverse sample of their population, as well as the 
longer duration of their study (seven years). 
The overall risk of developing cancer was significantly lower in patients treated by 
combination of biologics TNFi and bDMARDs (OR=0.3, 95% CI, 0.02-0.44, P=0.003).  
Mercer et al. (2015) in a five-year prospective study investigated RA patients enrolled in 
the British Society for Rheumatology Biologics Register. They compared the risk of solid 
cancer in RA patients treated with TNFi (n= 11,767) to that in patients treated with 
DMARDs (n=3,249). The authors did not find any difference in risk of solid cancer for 
TNFi compared to DMARD treated patients: They concluded that the addition of TNFi to 
DMARDs does not alter the risk of cancer in RA patients. Monotherapy with Etanercept 
showed significant lower risk of cancer in RA patients as compared to other biologic drugs 
(OR =0.10, 95% CI ,0.01-0.89, P=0.039). In 2017, Lan et al. conducted a retrospective 
population-based study of RA patients treated with TNFi. The main objective of their study 
was to explore the safety profile of TNFi and identify the potential benefit of Etanercept on 
the incidence of cancer. Their findings are reflective of our study findings, showing a 
reduced cancer risk in RA patients treated with Etanercept (HR =0.59, 95% CI, 0.36–0.98, 
P= 0.04). Similarly, in 2014, Morgan and colleagues in a prospective cohort of RA patients 
in the UK, examined the long-term safety of Etanercept in comparison with conventional 
DMARDs. Their study suggested that treatment with ETN was associated with improved 
survival, reduced risk of lymphoproliferative malignancy and a lower rate of cardiovascular 
events. Monotherapy with Rituximab in our study showed marginally non-significant 
 63 
increased cancer risk. However, since all Lymphomas and Breast cancers were diagnosed 
among patients who had exposure to this drug, the drug is still highlighted below. The 
author of this thesis believes there could be some degree of clinical relevance to this finding. 
Generally, Rituximab has been reported by most studies as a safe and effective drug that 
had shown no association with an increased risk of cancer (D. R. Chen & Cohen, 2012); 
(van Vollenhoven et al., 2010). However, two studies were found whose findings mirror 
those of ours. A study done by Tarella et al. (2010) examined the long-term outcome of a 
large series of patients with Lymphoma who received an intensive chemotherapy schedule 
(with or without addition of four to six doses of Rituximab). In their study, Rituximab 
addition was associated with a significant increased risk of solid tumor occurrence (SIR = 
3.19, 95% CI, 2.50 - 4.06, P= <0.001). Conversely, Rituximab in their study also had a 
significant protective role on the risk of death. Aaltonen et al. (2015) conducted a study to 
assess the incidence of serious infections and malignancies among patients with rheumatoid 
arthritis (RA) receiving either TNF inhibitor or rituximab (RTX) therapy. They reported 
the crude rates of malignancies to be highest among the patients treated with RTX (IR 9.5, 
95% CI 3.8–20).  In addition, all biologicals but RTX were associated with decreased risk 
for malignancy. However, after adding age and sex into the statistical model, the effect 
disappeared.  
    5.2 Pharmacokinetics of Rituximab   
 Rituximab is a B - lymphocyte-depleting agent. It was funded and developed by 
the National Cancer Institute (NCI) in 1997 to treat hematologic cancers mainly non-
Hodgkin Lymphoma (NHL) and chronic Lymphocytic Leukemia (CLL) 
https://www.cancer.gov/ and since been approved by the US Food and Drug Administration 
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and the European Medicines Agency in Europe for the treatment of RA in patients with 
poor response or intolerance to Tumor Necrosis Inhibitors (TNFi).  Rituxan works by 
primarily targeting a protein called CD20, which is found on the surface of white blood 
cells called B-lymphocytes (B-cells) (D. R. Chen & Cohen, 2012). Locking of Rituximab 
on to CD20, triggers the body’s immune system to attack the cells and destroy them. 
Unfortunately, such process destroys not only the abnormal (malignant) B-cells (that occur 
in many types of NHL and CLL) but also the normal B-cells - a process known as B-cell 
depletion (Looney, Srinivasan, & Calabrese, 2008). However, once treatment is complete 
the body supposedly can replace the normal B-cells over a certain time frame, a process 
that can usually take up to twelve months (Looney et.al., 2008).  This can lead to a question 
as to how vulnerable patients’ immune systems are during this window. Under normal 
circumstances antibodies such as B-cells are produced by the immune system to help fight 
infections and cancer formation. It is possible that more time is needed to see if repeated 
B-cell depletion is a safe and effective long-term treatment plan for Rheumatoid Arthritis 
and whether artificial interference with the immune system will increase susceptibility to 
malignancies (D. R. Chen & Cohen, 2012). 
Lastly, although the pro-cancer effect of chronic inflammation to initiate tumors has 
been well documented (Grivennikov et al., 2010), our study outcomes were unable to show 
any significant association between the developed malignancies and various inflammatory 
makers (CRP, ESR, DAS, HAQ and TSJC).  
Based on evidence from the existing literature, both chronic systemic inflammation 
(Ben-Neriah et al., 2011), therapy with Biologics (Bongartz et al., 2006) and/or MTX 
(Girish, Byrd, Roy, & Mehta 2003) can play a role in cancer formation. The general 
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perception is that PsA and RA patients who had severe inflammation where more likely to 
be treated with combination therapy (Biologics and MTX) and thus, were more likely to 
develop malignancy. In contrast, this study suggests that the risk of developing cancer was 
significantly reduced in patients treated with combination therapy and was not associated 
with disease severity. Clinically this can be explained by the effectiveness of combination 
therapy on the treatment of severe inflammation. According to literature severe 
inflammation is a known cancer risk factor (Ben-Neriah et al., 2011). By effectively 
treating severe inflammation and diminishing disease severity, a cancer risk factor is also 
eliminated. Statistically, the small number of events and short duration of follow up in our 
study could have affected our study results. Therefore, we cannot completely rule out 
potential associations that can be clinically significant. 
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5.3 Study Strengths Obstacles and Limitations 
5.3 a) Study Strengths 
The main strength of our study is that patients were seen in a real-world setting by 
a Canadian rheumatologist during routine clinical practice, which enhances the 
generalizability of the results to the target population. The patients came from across the 
province and were regularly treated and followed up in the Rheumatology clinic. To our 
knowledge, this is the first epidemiologic study in Newfoundland and Labrador to examine 
the incidence rates of malignancy in and between two-immune mediated inflammatory 
diseases (PsA and RA). In addition, our study had: 
           A relatively large sample size (N=700).  
           A geographic diversity with patients from various parts of the province.  
           A wide age range of the participants ranging from 21 to 96 years of age. 
          We used internationally standardized tools such as PASQ, HAQ, and DAS 28 to 
measure disease severity. 
 
5.3 b) Obstacles 
One of the challenges of clinical charts reviews is reliance on extracted data that 
was originally collected for reasons other than research. Obstacles included: incomplete 
documentation, missing charts, information that was unrecoverable or unrecorded, 
difficulty interpreting information found in the documents (e.g. acronyms, photocopies), 
etc. Out of a total of 805 eligible PsA and RA charts 2.7 % were missing and 6.5% were 
excluded from the study due to incomplete or difficulty in interpreting information that was 
relevant to the study (Fig.3.1). It is possible that some cancer patients could have been 
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missed with the exclusion of this charts. Such exclusion might have negatively affected the 
numbers of cancers in our study.  
 
5.3 c) Limitations 
 Our study has several limitations that would be important to note. There is 
a potential bias given the observational nature of the study, a bias that is avoided 
when using data from clinical trials. Without a random assignment to treatment it is 
difficult to infer causation between a drug of interest and risk of cancer occurrence. 
Confounding by indication may exist and may be responsible for differences 
between groups. Although our sample size of 700 people with PsA and RA is a 
representative sample of total NL population affected by arthritis; we cannot entirely 
exclude sampling bias. There is a possibility that patients seen at our specialty 
rheumatology clinic were more likely to have been healthier and were able to travel 
to the facility than the general population who might have consisted of sicker people 
been hospitalized for other comorbidities.  
Even though, all efforts were made to meticulously go through all 700 
patients’ charts, author cannot completely be certain that all patients with previous 
cancer were excluded. A prevalent sample of patients with PsA and RA was used to 
investigate cancer risk only for a period of 2011-2014. Some patients might have 
had the disease long before the study period. The variability of disease duration in 
these patients was between 9-13yrs. For example, patients with longer diseases 
duration could have more than one clinical chart which could have been archived 
and was beyond the authors reach.  
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We cannot entirely rule out that some malignancies may have not been 
captured. Approximately 9.0 % of our eligible study population charts were 
excluded due to incomplete information or missing charts. Such might have led to a 
possible selection bias. Furthermore, the main objective of our study was to 
investigate newly developed cancers during our study period (2011-2014).  Because 
of this we excluded patients with previous history of cancer from the study analysis. 
Patients with previous history of cancer are at high risk of developing a second 
cancer, by excluding this patient we could have lowered the cancer rates in our study 
population compared to controls who would have more cancers due to long life 
observation. However, this did not affect our study result as we did not find any 
difference in cancer rates between our study population and the general population.   
In this study, we did not have information on when patients started taking 
medication, switched over to new medication or stopped their treatment. Therefore, 
we only investigated the association between patients with history of exposure to 
treatment and cancers. The lack of detailed medication information limited us in our 
study analysis. For example, we were unable to do a time to event analysis and 
measure the effect of treatment overtime on cancers which would have provided us 
with more robust study results. It is also likely that patients might have been exposed 
to more than one medication at a time as most PsA and RA patients are known to be 
taking concomitant medication, therefore cross over medication effect cannot be 
completely ruled out. 
We did not have personal information on patient’s family history of cancer 
or their socio-economic status at the time of the study. Neither history of alcohol 
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consumption or other chronic diseases such as diabetes that can contribute to cancer 
formation. Patients with past family history of cancer have a greater risk of 
developing a second cancer. However, we would like to rule out prescription bias as 
we relied on the knowledge and judgement of the physicians that high risk cancer 
patients were not treated with TNFi or any other immunosuppressants and were not 
included in this study.  
 Not been able to adjust for confounders such alcohol use and diabetes in the 
study was a big limitation. According to the National Institute of Health (NIH) 
https://www.cancer.gov/ there is a strong scientific consensus of an association 
between alcohol drinking and several types of cancer such as (Breast, Colorectal, 
Esophageal etc.). Comorbidities such as Diabetes (especially type 2) has also been 
associated with an increased risk for some cancers such as liver, colon, breast and 
bladder cancers (Shikata, Ninomiya & Kiyohara, 2013).  
The four- year duration of our study, although sufficient, was not long 
enough to look at incidence cancers as an outcome. 
We chose to combine multiple cancers together in our outcome. One 
advantage of this is that the larger number of events increases statistical precision. 
However, the disadvantage is that the effect of specific cancer rates is obscured in 
analysis of the composite measure.  
 
5.3 d) Knowledge Translation 
The knowledge gained from this study was translated at local and international 
levels. Locally, the study protocol was disseminated by presenting to co-peers and faculty 
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during Clinical Epidemiology Seminar Series. The study findings were also presented via 
poster presentation at the 2018 “Annual Aldrich Interdisciplinary Graduate Research 
Conference” (Memorial University of Newfoundland). Internationally, the study abstract 
was accepted for publication by the Annual European Congress of Rheumatology (EULAR 
2018, Amsterdam, Netherlands). In the future we plan to further share our research findings 
with health care providers involved in the circle of RA and PsA patients care 
(rheumatologists, public health nurses, medical students/residents). Since this is the 1st 
study of this kind in the province, our findings (especially on treatment and risk of cancer) 
might be both interesting and useful to health care providers. This knowledge translation 
could help generate useful debates and discussions contents of which might be used for 
future cancer risk research in the NL population. It can also help raise awareness of this 
issue as well have a direct impact on patients quality of care. 
 
5.4 Suggestions for Future Studies 
A prospective longitudinal study, with information from various settings in the 
province, will be a better study design to look at the complete assessment of the relationship 
between cancer and patients with Psoriatic and Rheumatoid Arthritis. 
During our research, we discovered an information gap on the prevalence of cancer 
rates in the Newfoundland and Labrador general population. Knowing cancer prevalence 
for a province that has one of the highest cancer rates in Canada will help with better 
planning for health care needs for the prevalent population with cancer and cancer 
survivors.  
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Though a lot of work has been done by researchers to understand factors causing 
Rheumatoid Arthritis, the etiology of this chronic condition that lasts a lifetime is still 
unknown. Conducting a study that would try to better understand these factors in the NL 
population can help prevent future occurrence and burden of this disease in the province. 
 
5.5 Conclusion 
 This study suggests there is no significant difference in the cancer rate between our 
study and the NL general population. We also concluded that the analyzed data was 
reassuring due to OR values less than 1 (OR 0.3, P=0.003) for combined therapy of MTX 
and Biologics. Our study suggests further research on Rituximab is warranted. Even studies 
that have considered this drug to be safe and well tolerated, have advised of continuous and 
long-term monitoring and that only continued use and regular surveillance will show if 
repeated B-cell depletion is as safe as it now appears (D. R. Chen & Cohen, 2012). The 
Canadian Cancer Society 2016 report showed   the age standardized Incidence cancer rates 
(ASIR) for males and females to be highest in Newfoundland and Labrador (610.7 per 
100,000) http://www.cancer.ca/en/cancer. Inflammatory Arthritis is already a major public 
health burden, an addition of a cancer diagnosis will likely increase disease burden. Our 
findings add to the existing body of knowledge about Inflammatory Arthritis and incidence 
rates of cancer in the targeted population. More epidemiologic studies are required to 
determine the cancer prevalence in NL population. 
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APPENDICES 
 
APPENDIX A: 
Description of  Disease Activity Measuring Tools 
 
DAS 28-  Joint Disease Activity Score (DAS28):  is a well-established and validated tool 
that has been largely used to determine both disease activity and treatment response in both 
PsA and RA patients (Salaffi et al., 2014). This tool provides a global summative and 
continuous score for disease activity assessment and has been widely used in clinical trials 
as well as in practice (Heijde et al., 1993). 
The DAS28 scores provides ranges that corresponds to high, moderate, and low disease 
activity (table 1 and figure 1). High disease activity relates to DAS28 >5.1, moderate to 
DAS28 of >3.2 to 5.1, low disease activity is regarded in the range of 2.6 to 3.2. A cut-off 
points for “remission” has also been proposed (DAS28 <2.6). (www.uptodate.com ) 
 
DAS-28 Interpretation 
DAS-28 <2.6: Remission 
DAS-28 >=2.6 and <=3.2: Low Disease Activity 
DAS-28 >3.2 and <=5.1: Moderate Disease Activity 
DAS-28 >5.1: High Disease Activity 
 
 
The CASPAR Criteria: Is a diagnostic criterion based on 7 points that can be used to 
classify a patient as having psoriatic arthritis (PsA) (Taylor et al., 2006)  
 89 
A patient with inflammatory musculoskeletal disease such as peripheral arthritis, 
spondylitis, or enthesitis can be classified as having PsA, if a total of at least three points 
is accumulated from the presence of the following list of features each of which is 
assigned a certain number of points: 
 
1) Skin psoriasis that is: - Present – 2 points, OR 
2) Previously present by history – 1 point, OR 
3) A family history of psoriasis, if the patient is not affected – 1 point 
4) Nail lesions (onychosis, pitting) – 1 point 
5) Ductility’s (present or past, documented by a rheumatologist) – 1point 
6) Negative rheumatoid factor (RF) – 1 point 
7) Juxta-articular bone formation on radiographs (distinct from 
osteophytes) – 1 point 
 
 
Health Assessment Questionnaire (HAQ): is a comprehensive instrument designed to 
assess patient’ disability, discomfort, medication side effects, costs, and mortality (Smolen 
& Aletaha., 2012) www.uptodate.com  
       It is used frequently used in clinical trials and clinical practice to evaluate patients' 
ability to perform activities of daily living through their answers to 20 questions designed 
to assess upper or lower extremity use. These questions are organized into eight categories: 
dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each question is 
answered on a four-level scale of impairment ranging from 0 to 3: 0 = no difficulty; 1 = 
some difficulty; 2 = much difficulty; and 3 = inability to do activities of daily living 
(Smolen &Aletaha., 2012) www.uptodate.com  
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The final HAQ index, which ranges from 0 to 3, is the mean of scores from all eight 
categories. HAQ scores <0.3 are considered normal, however, the mean HAQ of the 
population rises with age. A higher HAQ scores indicate increasing disability. 
Psoriasis and Arthritis Screening Questionnaire (PASQ): is a sensitive and specific 
self-administered tool used for the Diagnosis of Early and Established Psoriatic Arthritis 
and to measure the degree of inflammatory symptoms. The PASQ questionnaire and 
diagram (Khraishi et.al., 2010) consists of 10 questions for which a positive and negative 
response are assigned a score of 1 and 0, respectively, with a maximum score of 10. Patients 
are also asked to indicate on the diagram where they experienced joint swelling or pain 
either at screening or in the past   the diagram is scored 0, 1, 3, or 5, depending on the 
distribution of the patients’ markings. Separate scores for the questionnaire (maximum of 
10) and the diagram (maximum of 5), are recorded as a composite score for each subject. 
 
  
 91 
                              
APPENDIX B: Ethics Approval and Renewal Letters 
 
 92 
 
  
 93 
  
 94 
 
APPENDIX C: Screenshot for PASQ 
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APPENDIX D: DAS 28 Visual Calculator 
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APPENDIX E: Psoriasis and Arthritis Screening Questionnaire 
  
 
Psoriasis and Arthritis Screening Questionnaire (PASQ) Questions 
Question Response 
Score for Positive 
Response 
1. Have you ever thought you might have arthritis? Yes, No 1 
2. Have you ever had a swollen joint? Yes, No 2 
3. Has a doctor ever told you that you have arthritis? Yes, No 2 
4. Are your joints stiff when you wake up in the morning? Yes, No 1 
4a. If yes to #4, how long does the stiffness last? ___ min ___ hr 1 if more than 30 min 
5. Have you ever had back troubles? Yes, No 0 
6. Has your back ever been stiff in the morning? Yes, No 0 
7. Do your fingernails or toenails have holes or ‘‘pits’’? Yes, No 1 
8. Do your fingernails come loose from the nail bed? Yes, No 1 for any 2 positives 
9. Are your nails abnormally thick? Yes, No responses to 7, 8, or 9 
10. Does anyone in your family have arthritis? Yes, No 0 
10a. If yes to #10, who? 0 
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APPENDIX F: Health Assessment Questionnaire (HAQ-DI) 
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